Evofem Biosciences has $78.8M working-capital deficit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Evofem Biosciences, Inc. (EVFM) reported third-quarter product sales of $4.628 million, compared with $4.952 million a year earlier, and net income of $1.004 million versus a $1.569 million loss. For the first nine months of 2026, product sales were $8.160 million, compared with $10.622 million in the same period of 2025, while net loss was $15.497 million versus $2.397 million.
At September 30, 2026, Evofem had a $78.8 million working-capital deficit and a $913.2 million accumulated deficit. The company said it lacked sufficient liquidity to meet obligations scheduled for December 1, 2026, including the Adjuvant Notes and Exchanged Senior Subordinated Notes, subject to their agreements and subsequent amendments. Management estimated available liquidity would not cover operating requirements and obligations as they come due for at least 12 months from issuance of the interim statements. The company concluded these circumstances raise substantial doubt about its ability to continue as a going concern. Its stated plans include additional financing, restructuring payables, product revenue, milestone payments if achieved, and potential licensing arrangements or business combinations.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter net income: $1.004 million, versus a $1.569 million loss.
Negative
- Major pointNine-month net loss: $15.497 million, versus $2.397 million in 2025.
- Major pointGoing-concern doubt: management cited insufficient liquidity for obligations for at least 12 months.
- Moderate pointThird-quarter product sales: $4.628 million, versus $4.952 million in 2025.
Filing Explained
At September 30, 2026, the notes carried conditional conversion capacity for 2,249,877,512 Adjuvant shares and 631,632,127 Exchanged SSN shares, not completed issuances.
The filing says shareholders approved a reverse split of 1-for-500 to 1-for-1,500 on
A reverse split consolidates shares and proportionally raises the per-share price, without changing company value by itself. At
Key Figures
Key Terms
going concern financial
working capital deficit financial
fair value option financial
variable consideration financial
beneficial ownership limitations financial
noncash interest expense financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were EVFM’s third-quarter 2026 sales and earnings?
When are EVFM’s Adjuvant Notes and Exchanged Senior Subordinated Notes due?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission
File Number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None |
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller reporting company
| ||
| Emerging growth company
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The
number of shares of the registrant’s Common Stock, $
Table of Contents
| Page | ||
| FORWARD-LOOKING STATEMENTS | 1 | |
| PART I. | FINANCIAL INFORMATION | |
| Item 1. | Financial Statements (Unaudited) | 3 |
| Condensed Consolidated Balance Sheets | 3 | |
| Condensed Consolidated Statements of Operations | 4 | |
| Condensed Consolidated Statements of Comprehensive Operations | 5 | |
| Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders’ Deficit | 6 | |
| Condensed Consolidated Statements of Cash Flows | 7 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 8 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 33 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 44 |
| Item 4. | Controls and Procedures | 44 |
| PART II. | OTHER INFORMATION | |
| Item 1. | Legal Proceedings | 46 |
| Item 1A. | Risk Factors | 46 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 46 |
| Item 3. | Defaults Upon Senior Securities | 46 |
| Item 4. | Mine Safety Disclosures | 46 |
| Item 5. | Other Information | 46 |
| Item 6. | Exhibits | 47 |
| Signatures | 48 | |
| Table of Contents |
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q (Quarterly Report) contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements include, among other things, statements about:
| ● | our ability to continue as a going concern; |
| ● | our ability to remediate the material weaknesses in our internal controls and procedures identified by management; |
| ● | our ability to obtain necessary approvals of any corporate action(s) needing stockholder or other approvals; |
| ● | our ability to effect the proposed reverse stock split, if determined appropriate by our Board of Directors, and the potential effects of such transaction on our stockholders and trading market; |
| ● | our ability to maintain an active trading market for our Common Stock; |
| ● | our ability to file Annual and Quarterly Reports on a timely basis; |
| ● | our ability to obtain sufficient additional capital, refinance or restructure existing indebtedness, and maintain adequate liquidity to fund our operations and satisfy our obligations as they become due; |
| ● | our ability to negotiate extensions, amendments or other restructuring arrangements with holders of our outstanding indebtedness; |
| ● | our ability to successfully execute our strategic initiatives, including potential licensing arrangements, commercial partnerships and other transactions intended to improve our liquidity and financial condition; |
| ● | our ability to achieve and sustain profitability; |
| ● | our estimates regarding expenses, revenues, financial performance, and capital requirements, including the length of time our capital resources will sustain our operations; |
| ● | the Notices of Default and cancellation of Forbearance Agreement received from Future Pak, LLC and any potential legal action(s) against the Company related thereto, including that its assets that could be foreclosed upon and potential negative outcome(s) thereof; |
| ● | our ability to comply with our debt obligations, repay or restructure outstanding indebtedness, including obligations scheduled to mature in December 2026, and avoid additional defaults, acceleration of indebtedness or enforcement actions by our creditors; |
| ● | our ability to successfully commercialize PHEXX® (lactic acid, citric acid and potassium bitartrate) vaginal gel (PHEXX) (formerly known as PHEXXI®) and SOLOSEC® (secnidazole) 2g oral granules (SOLOSEC); |
| ● | estimates regarding market size; |
| ● | estimates regarding health care providers’ (HCPs’) recommendations of PHEXX and SOLOSEC to patients; |
| ● | the rate and degree of market acceptance of PHEXX and SOLOSEC; |
| ● | our ability to successfully commercialize and distribute our products and continue to develop our sales and marketing capabilities; |
| ● | our strategic plans for our business, including the commercialization of our products; |
| ● | the potential for changes to current regulatory mandates requiring health insurance plans to cover U.S. Food and Drug Administration (FDA) -cleared or -approved contraceptive products without cost sharing; |
| ● | our ability to obtain or maintain third-party payer coverage and adequate reimbursement, and our reliance on the willingness of patients to pay out-of-pocket for our products absent full or partial third-party payer reimbursement; |
| ● | our ability to protect and defend our intellectual property position and our reliance on third party licensors; |
| ● | our ability to obtain additional patent protection for our products; |
| ● | our dependence on third parties for the manufacture of our products; |
| ● | our ability to expand our organization to accommodate potential growth; and |
| ● | our ability to retain and attract key personnel. |
| 1 |
| Table of Contents |
Forward-looking statements are based on management’s current expectations, assumptions and estimates and are subject to significant risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. These risks and uncertainties include, among others, those described in this Quarterly Report and under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as well as in our subsequent filings with the Securities and Exchange Commission (SEC). You should read this Quarterly Report and the documents that we have filed as exhibits hereto and incorporated by reference herein together with our other filings with the SEC. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time, that management cannot predict or assess. The forward-looking statements contained in this Quarterly Report speak only as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
This Quarterly Report contains estimates and other statistical data prepared by independent third parties and by the Company relating to market size, growth and other industry information. Such estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
Unless the context requires otherwise, references in this Quarterly Report to “Evofem,” “Company,” “we,” “us” and “our” refer to Evofem Biosciences, Inc. and its subsidiaries.
This Quarterly Report includes our trademarks, trade names and service marks, including “EVOFEM®”, “PHEXX®”, “FEMIDENCE™”, and “SOLOSEC®”, which are protected under applicable intellectual property laws and are the property of Evofem Biosciences, Inc. or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.
| 2 |
| Table of Contents |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except par value and share data)
| September 30, 2026 | December 31, 2025 | |||||||
| As of | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Restricted cash and cash equivalents | $ | $ | ||||||
| Trade accounts receivable, net | ||||||||
| Inventories | ||||||||
| Prepaid and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets | ||||||||
| Intangible asset, net (Note 7) | ||||||||
| Other noncurrent assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities, convertible and redeemable preferred stock and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Notes - carried at fair value (Note 4) | ||||||||
| Notes - carried at fair value - related party (Note 4) | ||||||||
| Convertible notes - Adjuvant - related party (Note 4) | ||||||||
| Convertible notes | ||||||||
| Short-term debt | ||||||||
| Accrued expenses | ||||||||
| Accrued compensation | ||||||||
| Operating lease liabilities – current | ||||||||
| Derivative liabilities | ||||||||
| Contingent liabilities - current (Note 7) | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities – noncurrent | ||||||||
| Contingent liabilities - noncurrent (Note 7) | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 7) | - | - | ||||||
| Convertible and redeemable preferred stock, $ | ||||||||
| Series E-1, F-1 and G-1 convertible and redeemable preferred stock, | ||||||||
| Convertible and redeemable preferred stock | ||||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock, $ | - | - | ||||||
| Common Stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit | $ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements (unaudited).
| 3 |
| Table of Contents |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share data)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Product sales, net | $ | $ | $ | $ | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Cost of goods sold | ||||||||||||||||
| Gain on change in accounting estimates on contingent royalty liability (Note 7) | - | ( | ) | - | ( | ) | ||||||||||
| Amortization of intangible asset | ||||||||||||||||
| Research and development, net | ( | ) | ||||||||||||||
| Selling and marketing | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses, net | ||||||||||||||||
| Income (loss) from operations | ( | ) | ||||||||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | - | |||||||||||||||
| Other expense, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss on debt extinguishment | ( | ) | - | ( | ) | - | ||||||||||
| Change in fair value of financial instruments | ( | ) | ( | ) | ( | ) | ||||||||||
| Total other income (expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Income (loss) before income tax benefit (expense) | ( | ) | ( | ) | ( | ) | ||||||||||
| Income tax benefit (expense) | - | ( | ) | |||||||||||||
| Net income (loss) | ( | ) | ( | ) | ( | ) | ||||||||||
| Convertible and redeemable preferred stock deemed dividends | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net income (loss) attributable to common stockholders | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted-average shares used to compute net income (loss) per share attributable to common shareholders: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
See accompanying notes to condensed consolidated financial statements (unaudited).
| 4 |
| Table of Contents |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS
(Unaudited)
(In thousands)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | ( | ) | ( | ) | ||||||||||||
| Reclassification adjustment related to debt extinguishment | - | - | ||||||||||||||
| Comprehensive income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
See accompanying notes to condensed consolidated financial statements (unaudited).
| 5 |
| Table of Contents |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE AND REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(Unaudited)
(In thousands, except share data)
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Deficit | |||||||||||||||||||||||||||||||||||||
Series E-1 Convertible and Redeemable Preferred Stock | Series F-1 Convertible and Redeemable Preferred Stock | Series G-1 Convertible and Redeemable Preferred Stock | Common Stock | Additional Paid-in | Accumulated Other Comprehensive | Accumulated | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Deficit | |||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2025 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
| Issuance of Common Stock upon noncash conversion of Series G-1 Shares | - | - | - | - | ( | ) | ( | ) | - | - | - | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Series E-1 and G-1 Shares dividends | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance as of March 31, 2026 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||||||||||||||
| Extinguishment of certain Exchanged SSNs | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Series E-1 and G-1 Shares dividends | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance as of June 30, 2026 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Extinguishment of certain Exchanged SSNs | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Series E-1 and G-1 Shares dividends | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2026 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Deficit | |||||||||||||||||||||||||||||||||||||
Series E-1 Convertible and Redeemable Preferred Stock | Series F-1 Convertible and Redeemable Preferred Stock | Series G-1 Convertible and Redeemable Preferred Stock | Common Stock | Additional Paid-in | Accumulated Other Comprehensive | Accumulated | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Deficit | |||||||||||||||||||||||||||||||||||||
| Balance as of December 31, 2024 | $ | $ | - | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Series E-1 Shares dividends | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Balance as of March 31, 2025 | $ | $ | - | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of Common Stock upon noncash exercise of purchase rights | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Issuance of Aditxt Notes – Related Party (Note 4) | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||||||||||||||
| Series E-1 Shares dividends | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance as of June 30, 2025 | $ | $ | - | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Balance | $ | $ | - | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of Common Stock upon noncash exercise of purchase rights | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
| Issuance of Series G-1 convertible and redeemable preferred stock upon conversion of convertible notes (Note 8) | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | - | - | - | - | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||||||||||||||
| Series E-1 and G-1 Shares dividends | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance as of September 30, 2025 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
See accompanying notes to condensed consolidated financial statements (unaudited).
| 6 |
| Table of Contents |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
| 2026 | 2025 | |||||||
| Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net restricted cash and cash equivalents used in operating activities: | ||||||||
| Loss on debt extinguishment | - | |||||||
| Gain on change in accounting estimates on contingent royalty liability | - | ( | ) | |||||
| Change in fair value of financial instruments | ||||||||
| Inventory write-down for excess & obsolescence | ||||||||
| Loss on contingent liability | ||||||||
| Stock-based compensation | ||||||||
| Depreciation | ||||||||
| Amortization of intangible asset | ||||||||
| Noncash interest expense | ||||||||
| Noncash right-of-use asset amortization | ||||||||
| Net loss on disposal or impairment of property and equipment | - | |||||||
| Gain on accounts payable and accrued expenses settlements | ( | ) | ( | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Trade accounts receivable | ||||||||
| Inventories | ( | ) | ( | ) | ||||
| Prepaid and other assets | ||||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses and other liabilities | ( | ) | ||||||
| Accrued compensation | ( | ) | ||||||
| Contingent liabilities | ( | ) | ( | ) | ||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net restricted cash and cash equivalents used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Payments related to intangible asset acquisition | - | ( | ) | |||||
| Purchases of property and equipment | ( | ) | ( | ) | ||||
| Net restricted cash and cash equivalents used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of Aditxt Notes – Related Party | - | |||||||
| Borrowings under short-term debt | ||||||||
| Payments under short-term debt and Notes – carried at fair value | ( | ) | ( | ) | ||||
| Net restricted cash and cash equivalents provided by financing activities | ||||||||
| Net change in restricted cash and cash equivalents | ( | ) | ||||||
| Restricted cash and cash equivalents, beginning of period | ||||||||
| Restricted cash and cash equivalents, end of period | $ | $ | ||||||
| Supplemental disclosure of noncash investing and financing activities: | ||||||||
| Addition to ROU asset and lease liability due to new leases | $ | - | $ | |||||
| Exchange of convertible notes to Series G-1 convertible and redeemable preferred stock | - | |||||||
| Series E-1 Shares and Series G-1 Shares deemed dividends | ||||||||
| Issuance of Common Stock upon exercise of purchase rights | - | |||||||
| Issuance of Common Stock upon conversion of Series G-1 Shares | - | |||||||
| Net decrease in contingent liabilities | ||||||||
See accompanying notes to condensed consolidated financial statements (unaudited).
| 7 |
| Table of Contents |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Description of Business and Basis of Presentation
Description of Business
Evofem is a San Diego-based commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first commercial product, PHEXX®, was approved by the FDA on May 22, 2020, for the prevention of pregnancy and launched in the U.S. in September 2020. PHEXX is the first and only non-hormonal prescription contraceptive vaginal gel. Women use it when they have sex, applying PHEXX 0-60 minutes prior to intercourse. Because PHEXX is hormone-free and non-systemic, it is not associated with the common side effects of hormonal contraceptive methods, which include depression, weight gain, headaches, loss of libido, mood swings and irritability. Taking hormones may not be right for some women, especially those with certain medical conditions including but not limited to, blood clotting disorders, hormone-sensitive cancers, diabetes, those who have a BMI over 30, as well as women who are breast feeding, and / or who smoke. Per the National Center for Health Statistics (NCHS), based on data from the 2022-2023 National Survey of Family Growth, approximately 15.9 million women1 in the U.S. do not want to get pregnant and will not use a hormonal contraceptive.
The Company acquired global rights to SOLOSEC® on July 14, 2024 and relaunched the brand in November 2024. SOLOSEC is an FDA-approved single-dose oral antimicrobial agent that provides a complete course of therapy for the treatment of two common sexual health infections – bacterial vaginosis (BV) and trichomoniasis (Trich). We believe this acquisition aligns with and helps to advance the Company’s mission to commercialize innovative and differentiated products for women’s sexual and reproductive health.
Outside the U.S., the Company’s current strategy is to commercialize its products in global markets through commercial partnerships and/or license agreements.
| - | The Company licensed commercial rights to PHEXX and SOLOSEC in the Middle East and North Africa (MENA) to Pharma 1 Drug Store, LLC (Pharma 1), an emerging Emirati health care company, in July 2024 and May 2025, respectively. Pharma 1 filed for regulatory approval of PHEXX in the United Arab Emirates (UAE) in June 2025 and of SOLOSEC in the UAE in September 2025. The Emirates Drug Establishment (EDE) issued favorable pricing certificates for PHEXX in November 2025. | |
| - | In April 2026, the Company entered into a Distributorship Agreement with Clovis Davis Pharmaceuticals, LLC. (Clovis Davis) for distribution of SOLOSEC in sub-Saharan Africa. Regulatory work is underway for SOLOSEC in Uganda, the first planned market under this agreement. |
Basis of Presentation and Principles of Consolidation
The Company prepared the unaudited interim condensed consolidated financial statements included in this Quarterly Report in accordance with accounting principles generally accepted (GAAP) in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q.
The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited consolidated financial statements and should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2025 included in its Annual Report on Form 10-K as filed with the SEC on March 11, 2026 (the 2025 Audited Financial Statements).
1 Daniels K and Abma J. Current Contraceptive Status Among Females Ages 15–49: United States, 2022–2023. NCHS Data Brief No. 539. August 2025. Data table for Figure 1, sourced from National Survey of Family Growth (NSFG) 2022–2023. https://www.cdc.gov/nchs/data/databriefs/db539.pdf
| 8 |
| Table of Contents |
The unaudited interim condensed consolidated financial statements included in this Quarterly Report have been prepared on the same basis as the Company’s audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statements of convertible and redeemable preferred stock and stockholders’ deficit for the periods presented. The results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results expected for the full year. The condensed consolidated balance sheet as of December 31, 2025 was derived from the 2025 Audited Financial Statements.
Reverse Stock Split
On November 26, 2025, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of Common Stock at a ratio ranging from 1-for-500 to 1-for-1,500, with the final ratio to be determined by the Company’s Board of Directors. The Company’s board of directors has not effectuated the reverse stock split as of the date of filing of this Quarterly Report.
Risks, Uncertainties and Going Concern
Any disruptions in the commercialization of PHEXX or SOLOSEC and/or their supply chains could have a material adverse effect on the Company’s business, results of operations and financial condition. The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.
The
Company’s principal operations are related to the commercialization of PHEXX and, since July 2024, SOLOSEC. Additional activities
have included raising capital, identifying alternative manufacturing to lower PHEXX cost of goods sold (COGS), re-establishing the manufacturing
/ supply chain for SOLOSEC, seeking ex-U.S. licensing partners to add non-dilutive capital to the balance sheet and geographically diversify
its revenue streams, seeking product in-licensing/acquisition opportunities to expand and diversify its U.S. revenue streams, and establishing
and maintaining a corporate infrastructure to support commercial products. The Company has incurred operating losses and negative cash
flows from operating activities since inception, excluding non-recurring accounts payable and accrued expenses settlements, debt extinguishments,
and changes in accounting estimates in certain prior periods. As of September 30, 2026, the Company had a working capital deficit of
$
The Company also faces significant near-term debt obligations, including the Adjuvant Notes and Exchanged Senior Subordinated Notes, which are currently scheduled to mature on December 1, 2026, subject to the terms of the applicable agreements and any subsequent amendments. The Company does not currently have sufficient liquidity to satisfy these obligations at maturity and will need to obtain additional financing, negotiate extensions or restructurings, or pursue other alternatives. There can be no assurance that the Company will be successful in doing so, and failure to satisfy or restructure these obligations could result in additional defaults, enforcement actions and other material adverse consequences to the Company’s business, financial condition and ability to continue as a going concern.
Management’s plans to meet its cash flow needs in the next 12 months includes generating recurring product revenue from PHEXX and SOLOSEC, earning milestone payments triggered by the achievement of certain regulatory milestones under the License and Supply Agreement with Pharma 1 for SOLOSEC, if achieved, generating product revenue from the sale of PHEXX and SOLOSEC to Pharma 1 and SOLOSEC to Clovis Davis for approved countries, if any, in the respective licensed Territories, restructuring its current payables, and obtaining additional funding through non-dilutive or dilutive financings, collaborations or partnerships with other companies, including license agreements for PHEXX and/or SOLOSEC in the U.S. or foreign markets, or through other potential business combinations.
| 9 |
| Table of Contents |
The Company anticipates it will continue to incur net losses for the foreseeable future. According to management estimates, liquidity resources are not sufficient to fund its operating requirements and satisfy its obligations as they come due, for at least twelve months from the date of issuance of these interim condensed consolidated financial statements.
If the Company is not able to obtain the required funding through a significant increase in revenue, license agreements for PHEXX and/or SOLOSEC, equity or debt financings, or other means, or is unable to obtain funding on terms favorable to the Company, or if the Company’s creditors seek to enforce existing alleged defaults or additional events of default occur under its outstanding debt arrangements there will be a material adverse effect on commercialization operations and the Company’s ability to execute its strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, the Company may be forced to make further reductions in spending, including spending in connection with its commercialization activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in the condensed consolidated financial statements, suspend or curtail planned operations, or cease operations entirely. Any of these could materially and adversely affect the Company’s liquidity, financial condition and business prospects, and the Company would not be able to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the interim condensed consolidated financial statements and the notes thereto.
Significant estimates affecting amounts reported or disclosed in the interim condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the allowance for expected credit losses estimate; the assumptions used in estimating the notes carried at fair value, preferred stock, and purchase rights; and the assumptions used in the valuation of inventory, the intangible asset, and contingent liabilities; the useful lives and recoverability of long-lived assets; and the valuation of deferred tax assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. These estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.
Segment Reporting
Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker (CODM), the Chief Executive Officer of the Company, in making decisions regarding resource allocation
and assessing performance. The Company views its operations and manages its business in
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of restricted cash and cash equivalents. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.
The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its restricted cash and cash equivalent balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.
The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and, starting in the fourth quarter of 2025, in the United Arab Emirates (UAE), and consist of wholesale distributors, retail pharmacies, mail-order specialty pharmacies, five sites participating in the Phase 4 NIH-funded clinical trial, and, in the UAE, its licensee, Pharma 1.
| 10 |
| Table of Contents |
In the U.S., products are distributed primarily through three major distributors and mail-order pharmacies, which receive service fees calculated as a percentage of the gross sales and a fee-per-unit shipped or sold, respectively. These entities are not obligated to purchase any set number of units; they distribute products on demand as orders are received.
For
the three and nine months ended September 30, 2026, the Company’s three largest customers combined made up approximately
Significant Accounting Policies
There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies of the 2025 Audited Financial Statements in the Company’s Annual Report.
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents consist of cash in checking accounts, money market funds and time deposit accounts that are subject to contractual restrictions on their use, including restrictions imposed under certain of the Company’s financing arrangements. Such amounts are classified as restricted cash and cash equivalents in the condensed consolidated balance sheets because they are not available for unrestricted general corporate purposes.
Net Income (Loss) Per Share
Basic
net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the
weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities.
The net income (loss) available to common stockholders is adjusted for amounts in accumulated deficit related to the deemed
dividends triggered for certain financial instruments. Such adjustment was $
The schedule of potentially dilutive securities excluded from the calculation of diluted net income (loss) per share is included below:
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Income (Loss) Per Share
| 2026 | 2025(1) | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025(1) | |||||||
| Options to purchase Common Stock | ||||||||
| Warrants to purchase Common Stock | ||||||||
| Series E-1 Shares | ||||||||
| Series F-1 Shares | ||||||||
| Series G-1 Shares | ||||||||
| Purchase rights to purchase Common Stock | ||||||||
| Convertible debt | ||||||||
| Total(2) | ||||||||
| (1) | |
| (2) |
The following table sets forth the computation of net income attributable to common shareholders, weighted average common shares outstanding for diluted net income per share, and diluted net income per share attributable to common shareholders for the three months ended September 30, 2026 (in thousands, except share and per share amounts):
Schedule of Weighed Average Common Shares Outstanding for Diluted Net Loss Per Share
| Three Months Ended September 30, 2026 | ||||
| Numerator: | ||||
| Net income attributable to common stockholders | $ | |||
| Adjustments: | ||||
| Noncash interest expense on convertible debt, net of tax | ||||
| Change in fair value of purchase rights | ( | ) | ||
| Net loss attributable to common stockholders | $ | ( | ) | |
| Denominator: | ||||
| Weighted average shares used to compute net income attributable to common stockholders, basic | ||||
| Add: | ||||
| Pro forma adjustments to reflect assumed conversion of convertible debt | ||||
| Pro forma adjustments to reflect assumed exercise of outstanding purchase rights | ||||
| Pro forma adjustments to reflect assumed conversion of Series E-1 Shares | ||||
| Pro forma adjustments to reflect assumed conversion of Series F-1 Shares | ||||
| Pro forma adjustments to reflect assumed conversion of Series G-1 Shares | ||||
| Pro forma adjustments | ||||
| Weighted average shares used to compute net income attributable to common stockholders, diluted | ||||
| Net loss per share attributable to common stockholders, diluted | $ | ( | ) | |
| 11 |
| Table of Contents |
Correction of Previously Issued Interim Condensed Consolidated Financial Statements and Prior Period Errors
In
the fourth quarter of 2025, the Company identified issues with the disclosure of the weighted-average shares outstanding and the basic
and diluted earnings per share calculations. First, the prefunded warrants should have been included in the weighted-average shares outstanding
in the disclosure of basic and diluted earnings per share for the three and nine months ended September 30, 2025. Correcting this calculation
resulted in an increase in the weighted-average shares outstanding of
Recently Adopted Accounting Pronouncements
In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, designed to clarify the requirements for accounting for the settlement of a debt as an induced conversion versus as an extinguishment. This guidance was effective for the Company on January 1, 2026 and the Company will apply the guidance on any future induced debt conversions.
In July 2025, the FASB issued ASU 2025-05, Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, to provide a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under Accounting Standards Codification (ASC) 606 whereby companies are allowed to assume that current economic conditions will not change over the remaining life of current accounts receivable. The Company adopted ASU 2025-05 on January 1, 2026, but because the Company does not currently expect any credit losses for accounts receivable and does not have any contract assets, there was no impact to the Company’s unaudited condensed consolidated financial statements.
No other significant new standards have been adopted during the nine months ended September 30, 2026.
Recently Issued Accounting Pronouncements — Not Yet Adopted
From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted as of the specified effective date.
In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, designed to clarify or improve disclosure and presentation requirements on a variety of topics and align the requirements in the FASB ASC with the SEC regulations. This guidance is effective for the Company no later than June 30, 2027. The Company is still evaluating the impact of ASU 2023-06.
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which primarily requires disaggregation of specific expense categories in disclosures within the footnotes on an annual and interim basis. ASU 2024-03 is effective for the Company’s annual period ending December 31, 2027 and interim periods thereafter. Early adoption is permitted. In January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. The Company is still evaluating the impacts of ASU 2024-03 and ASU 2025-01.
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, to improve the guidance in ASC 270 related to interim reporting and also to clarify when it applies. This guidance is effective for the Company no later than January 1, 2028. The Company is still evaluating the impact of ASU 2025-11.
In December 2025, the FASB issued ASU 2025-12, Codification Improvements, to update the FASB ASC for a broad range of topics arising from technical corrections, unintended application of the ASC, clarifications, and other minor improvements. This guidance is effective for the Company no later than January 1, 2027. The Company is still evaluating the impact of ASU 2025-12.
In April 2026, the FASB issued ASU 2026-01, Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock, to add guidance on how companies should measure paid-in-kind dividends on equity-classified preferred stock. The guidance is effective for the Company no later than January 1, 2027. The Company is still evaluating the impact of ASU 2026-01.
The Company does not believe the impact of any other recently issued standards and any issued but not yet effective standards will have a material impact on its unaudited condensed consolidated financial statements upon adoption.
| 12 |
| Table of Contents |
3. Revenue
In accordance with ASC 606, the Company recognizes revenue when its performance obligation is satisfied by transferring control of the product to a customer. Any payments received before the Company satisfies its performance obligations are considered deferred revenue until the obligations are satisfied. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer.
The
Company’s customers are primarily located in the U.S. and consist of wholesale distributors, retail pharmacies, mail-order
specialty pharmacies, five sites participating in the Phase 4 NIH-funded clinical trial, and, in the UAE, its licensee, Pharma 1.
The first order for PHEXX from the UAE was placed in late 2025 and will be manufactured for and sold to Pharma 1 following Emirates
Drug Establishment approval of the product. For all customers, payment terms typically range from
The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when the performance obligation is satisfied. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue.
The Company’s products are sold to domestic customers at the Wholesale Acquisition Cost (WAC), or in some cases at a discount to WAC. However, the Company records product revenue net of reserves for applicable variable consideration. These types of variable consideration reduce revenue and include the following:
| ● | Distribution services fees | |
| ● | Prompt pay and other discounts | |
| ● | Product returns | |
| ● | Chargebacks | |
| ● | Rebates | |
| ● | Patient support programs, including our co-pay programs |
In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relies on historical sales data showing the amount of various end-user consumer types, inventory reports from the wholesale distributors and mail-order specialty pharmacy, and other relevant data reports.
The specific considerations that the Company uses in estimating these amounts related to variable consideration are as follows:
Distribution services fees – The Company pays distribution service fees to its wholesale distributors and mail-order specialty pharmacies. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount or distributor’s sales of products for certain wholesale distributors. The Company considers these fees to be separate from the customer’s purchase of the product and, therefore, they are recorded in other current liabilities on the condensed consolidated balance sheets.
Prompt pay and other discounts – The Company incentivizes its customers to pay their invoices on time through prompt pay discounts. These discounts are an industry standard practice, and the Company offers a prompt pay discount to each wholesale distributor and retail pharmacy customers. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are typically taken by the Company’s customers. The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. An estimate of the prompt pay discounts and other discounts are recorded at the time of sale based on the purchase amount as contra trade accounts receivable on the condensed consolidated balance sheets.
| 13 |
| Table of Contents |
Product returns – Domestic customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than twelve months. PHEXX has a shelf life of 48 months. SOLOSEC has a shelf life of 60 months. The Company uses historical sales and return data to estimate future product returns. Product return estimates are recorded as other current liabilities on the condensed consolidated balance sheets.
Chargebacks – Certain government entities and covered entities (e.g., Veterans Administration, 340B covered entities, group purchasing organizations) are able to purchase products at a price discounted below WAC. The difference between the government or covered entity purchase price and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount of each chargeback channel based on the expected number of claims in each channel and related chargeback that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the condensed consolidated balance sheets.
Rebates – The Company is subject to mandatory discount obligations under the Medicaid and Tricare programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates for Medicaid and Tricare are invoiced in arrears. The Company has numerous commercial rebate programs for its products whereby certain customers receive a rebate as contractually arranged; the program for PHEXX ended on December 31, 2025. The Company estimates the amount of rebates based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as other current liabilities on the condensed consolidated balance sheets.
Patient support programs – The Company voluntarily offers a co-pay program to provide financial assistance to patients meeting certain eligibility requirements. The Company estimates the amount of financial assistance for these programs based on the expected number of claims and related cost associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Patient support program estimates are recorded as other current liabilities on the condensed consolidated balance sheets.
The
variable consideration discussed above was recorded in the condensed consolidated balance sheets and consisted of $
4. Debt
Baker Notes (owned by Future Pak, LLC since July 23, 2024)
On
April 23, 2020, the Company entered into a Securities Purchase and Security Agreement (the Baker Bros. Purchase Agreement) with
certain affiliates of Baker Bros. Advisors LP, as purchasers (the Baker Purchasers), and Baker Bros. Advisors LP, as designated
agent, pursuant to which the Company agreed to issued pursuant to which the Company issued senior secured promissory notes in an
aggregate principal amount of $
| 14 |
| Table of Contents |
The Baker
Notes bear interest at a rate of
The Fourth Baker Amendment also provides the Company with the right to repurchase the Baker Notes at specified amounts
during designated periods.
On July 23, 2024, the Baker Notes were assigned to Future Pak, LLC (Future Pak). The Company accounted for the assignment as a debt extinguishment and recognized the reassigned Baker Notes at fair value. The Baker Notes are accounted for under the fair value option pursuant to ASC 825, with changes in fair value attributable to the Company’s own credit risk recognized in other comprehensive income (loss) and other changes in fair value recognized in the condensed consolidated statements of operations.
As of September 30, 2026,
the Baker Notes had an aggregate outstanding principal and accrued interest balance of approximately $
Notices of Default
On September 27, 2024, Future Pak, as designated agent, delivered a notice alleging events of default under the Baker Bros. Purchase Agreement arising from certain payment arrangements entered into by the Company with existing creditors, including the U.S. Department of Health and Human Services. Future Pak subsequently delivered amended notices on October 27, 2024 and November 8, 2024, alleging additional defaults, including the Company’s failure to maintain a minimum cash balance and timely deliver certain financial and operating reports. Future Pak also asserted that the applicable forbearance agreement had terminated and that repayment obligations under the Baker Notes had been accelerated. Under the Baker Bros. Purchase Agreement, upon certain events of default, holders may elect to require the Company to repurchase their Baker Notes at an amount equal to two times the outstanding principal and accrued interest, subject to the terms of the applicable agreements. The Company disputes the alleged events of default and Future Pak’s asserted rights and remedies. As of September 30, 2026, the alleged defaults had not been waived or cured. The Company intends to contest any attempt by Future Pak to enforce its asserted rights and remedies under the Baker Bros. Purchase Agreement. If Future Pak successfully enforces such rights, the Company could face substantial payment obligations or foreclosure upon its assets, which could materially adversely affect its liquidity, financial condition, operations and ability to continue as a going concern.
See Note 6 — Fair Value of Financial Instruments for additional information regarding the valuation of the Baker Notes.
Adjuvant Notes
On
October 14, 2020, the Company entered into a Securities Purchase Agreement (as amended, the Adjuvant Purchase Agreement) with
Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (collectively, Adjuvant), pursuant
to which the Company issued unsecured convertible promissory notes in aggregate principal amount of $
The
Adjuvant Notes bear interest at
On
August 22, 2025, the Company entered into an Exchange Agreement with Adjuvant providing for the exchange of a portion of the Adjuvant
Notes due in the aggregate original principal and accrued interest amount of approximately $
As
of September 30, 2026, the conversion price was $
On April 10, 2026, the Company and Adjuvant entered into the Fourth Amendment to the Adjuvant Purchase Agreement, which extended the maturity date of the Adjuvant Notes to the earlier of (i) October 10, 2026, (ii) at Adjuvant’s election, the consummation of a change of control, and (iii) acceleration of the Adjuvant Notes in accordance with their terms. The Fourth Amendment also restricted prepayment of the Adjuvant Notes prior to October 10, 2026 without Adjuvant’s prior written consent.
| 15 |
| Table of Contents |
On October 9, 2026, the Company and Adjuvant entered into the Fifth amendment to the Adjuvant Purchase Agreement (the Adjuvant Fifth Amendment). which further extended the maturity date to the earlier of (i) December 1, 2026, (ii) at Adjuvant’s election, the consummation of a change of control, and (iii) acceleration of the Adjuvant Notes in accordance with their terms. The Fifth Amendment also prohibits prepayment prior to December 1, 2026 without Adjuvant’s prior written consent. See Note 10 — Subsequent Events.
The
Adjuvant Notes are accounted for in accordance with authoritative guidance for convertible debt instruments and are classified as current
liabilities in the condensed consolidated balance sheets. The aggregate proceeds of $
Term Notes
Original SSNs and Exchanged SSNs
The
Company entered into eight Securities Purchase Agreements (SPAs) between December 2022 and September 2023 with certain investors; each
of the agreements was materially similar. Pursuant to each SPA, the Company agreed to sell in a registered direct offering (i) unsecured
On December 1, 2023, the Company entered into restructuring agreements with the holders of the Original SSNs, pursuant to which the Company and each holder agreed to, among other things, (i) change the governing law and jurisdiction of the Original SSNs from New York to Delaware and (ii) reissue the Original SSNs (the Exchanged SSNs) under Section 3(a)(9) exemption of the Securities Act of 1933, as amended (the Restructuring Agreements). The maturity date of the Exchanged SSNs is December 1, 2026. No new consideration was paid and, other than the maturity date, no other terms of the Original SSNs were changed in conjunction with the Restructuring Agreements.
Assuming
conversion of the entire outstanding principal at the applicable conversion price per share, the Exchanged SSNs could be converted into
The
Exchanged SSNs’ interest rates are subject to increase to
The Company evaluated the Original SSNs in accordance with ASC 480 and determined that the Original SSNs were all liability instruments at issuance. The applicable Original SSNs were then evaluated in accordance with the requirements of ASC 825 and the Company concluded that they were not precluded from electing the fair value option for the applicable Original SSNs.
Pursuant to the Restructuring Agreements, the Company evaluated the Exchanged SSNs under ASC 470, and concluded that the exchange represented a non-substantial modification of the Original SSNs. Accordingly, the Company accounted for the Exchanged SSNs as a modification of the Original SSNs rather than as an extinguishment which would require derecognizing the fair value of Original SSNs and related accumulated other comprehensive loss and replacing them with the fair value of the Exchanged SSNs.
The Company also evaluated the Warrants in accordance with ASC 480 and as of both September 30, 2026 and December 31, 2025, determined the warrants should be classified as equity instruments as of each date.
As
described in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit, on August 22, 2025, the Company
entered into Exchange Agreements with certain SSN holders providing for the exchange of a portion of the SSNs due in the aggregate original
principal and accrued interest amount of approximately $
On
June 29, 2026, and July 2, 2026, HUB Cyber Security Ltd. (HUB), a foreign private issuer incorporated in Israel and listed on Nasdaq,
acquired a portion of the Exchanged SSNs from certain of the original holders (the June 2026 SSN Purchase and the July 2026 SSN Purchase,
together the 2026 SSN Purchases). The Company was not involved in either transaction and did not receive any remuneration as part of
the transactions. The portion of the Exchanged SSNs that were sold to HUB are included within the Exchanged SSNs since they have the
same terms and maturity date as the Exchanged SSNs. As of September 30, 2026, the principal of the Exchanged SSNs owned by HUB was $
Upon
each of the 2026 SSN Purchases, the Company reviewed the Exchanged SSNs in accordance with ASC 470. The portion of the Exchanged
SSNs that were sold to HUB, having been effectively terminated in each purchase, were extinguished on June 29, 2026 and July 2,
2026, resulting in removing the fair value of the effected Exchanged SSNs of $
| 16 |
| Table of Contents |
Aditxt Notes and Warrants
On
April 8, 2025 and June 26, 2025, the Company entered into securities purchase agreements with Aditxt, Inc. pursuant to which the Company
issued unsecured senior subordinated convertible notes in the aggregate original principal amounts and warrants to purchase shares of
Common Stock as listed in the chart below. The Company received approximately $
The
Aditxt Notes bear interest at
The Company evaluated the Aditxt Notes in accordance with ASC 480 and determined that the notes were all liability instruments at issuance. The notes were then evaluated in accordance with the requirements of ASC 825 and the Company concluded that they were not precluded from electing the fair value option.
The Company evaluated the Aditxt Warrants in accordance with ASC 480 and ASC 815 and concluded that the instruments meet the criteria for classification as equity as of September 30, 2026 and December 31, 2025.
As
of September 30, 2026, the Aditxt Notes had an aggregate outstanding principal and accrued interest balance of approximately $
| 17 |
| Table of Contents |
Summary of Aditxt Notes, Exchanged SSNs and Warrants at Issuance (December 2022 to September 2023 and April to June 2025):
Schedule of SSNs and Warrants
| Principal At | Net Proceeds Before | |||||||||||||||||
| Notes | Issuance (in Thousands) | Issuance costs (in Thousands) | Common Warrants | Preferred Shares | Current Maturity Date | |||||||||||||
| December 2022 Notes(4) | $ | $ | ||||||||||||||||
| February 2023 Notes(1)(4) | - | |||||||||||||||||
| March 2023 Notes(4) | - | |||||||||||||||||
| March 2023 Notes(2)(4) | - | |||||||||||||||||
| April 2023 Notes(4) | - | |||||||||||||||||
| July 2023 Notes(4) | - | |||||||||||||||||
| August 2023 Notes(4) | - | |||||||||||||||||
| September 2023 Notes(3)(4) | - | |||||||||||||||||
| Aditxt April Note | - | |||||||||||||||||
| Aditxt June Note | - | |||||||||||||||||
| Total Offerings | $ | $ | ||||||||||||||||
| (1) | |
| (2) | |
| (3) | |
| (4) |
Short-term Debt
July 2026 HUB Note
On
July 8, 2026, the Company issued a subordinated promissory note with HUB providing for the sale and issuance of a subordinated note due
in the aggregate original principal and net proceeds amount of $
The July 2026 HUB Note contains customary affirmative and negative covenants, including restrictions on the Company’s ability to enter into mergers, consolidations and other business combinations, dispose of substantially all of its assets, materially change its business operations, amend its organizational documents or undertake certain other corporate actions without HUB’s prior written consent. The July 2026 HUB Note also contains customary events of default, including failure to make required payments when due.
As of September 30, 2026, the July 2026 HUB Note had an aggregate outstanding principal, accrued interest, and accrued fees balance of
approximately $
Insurance Premium Finance Agreement
In
June 2025, the Company entered into an insurance premium finance agreement with First Insurance Funding (FIF) to finance a portion of
its current year’s D&O and general insurance policies. The total amount financed was $
On
May 29, 2026, the Company entered into an insurance premium finance agreement with FIF to finance a portion of its current year’s
D&O and general insurance policies. The total amount financed was $
5. Balance Sheet Details
Inventories
Inventories consist of the following (in thousands):
Schedule of Inventories
| September 30, 2026 | December 31, 2025 | |||||||
| Raw materials | $ | $ | ||||||
| Work in process | ||||||||
| Finished goods | ||||||||
| Total | $ | $ | ||||||
| 18 |
| Table of Contents |
Prepaid and Other Current Assets
Prepaid and other current assets consist of the following (in thousands):
Schedule of Prepaid and Other Current Assets
| September 30, 2026 | December 31, 2025 | |||||||
| Insurance | $ | $ | ||||||
| Receivable from Pharma 1 | ||||||||
| Short-term deposits | ||||||||
| Other | ||||||||
| Total | $ | $ | ||||||
Property and Equipment, Net
Property and equipment, net, consists of the following (in thousands):
Schedule of Property and Equipment Net
| Useful Life | September 30, 2026 | December 31, 2025 | ||||||||
| Research equipment | $ | $ | ||||||||
| Computer equipment and software | ||||||||||
| Construction in-process | - | |||||||||
| Property and equipment, gross | ||||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||||
| Total, net | $ | $ | ||||||||
Depreciation expense for property and equipment was immaterial in each of the three and nine months ended September 30, 2026 and 2025.
Intangible Asset, Net
Intangible asset, net, consists of the following (in thousands):
Schedule of Intangible Assets, Net
| Useful Life | September 30, 2026 | December 31, 2025 | ||||||||
| Intellectual property | $ | $ | ||||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||||
| Total, net | $ | $ | ||||||||
The
Company’s intangible asset consists of intellectual property acquired in connection with the SOLOSEC asset acquisition in
July 2024 and as described further in Note 7 – Commitments and Contingencies, the useful life is based on
the SOLOSEC IP patent expiration. Amortization expense was immaterial and $
| 19 |
| Table of Contents |
6. Fair Value of Financial Instruments
Fair Value of Financial Liabilities
The following tables summarize the Company’s convertible debt instruments as of September 30, 2026 and December 31, 2025, respectively (in thousands):
Schedule of Fair Value of Financial Liabilities
| Principal | Accrued | Net Carrying | Fair Value | |||||||||||||||
| As of September 30, 2026 | Amount | Interest | Amount | Amount | Leveling | |||||||||||||
| Baker Notes(1)(2) | $ | $ | - | $ | $ | Level 3 | ||||||||||||
| Adjuvant Notes(3) | N/A | N/A | ||||||||||||||||
| Exchanged SSNs(1) (4) | - | Level 3 | ||||||||||||||||
| Aditxt Notes(1) | - | Level 3 | ||||||||||||||||
| Totals | $ | $ | $ | $ | N/A | |||||||||||||
| Principal | Accrued | Net Carrying | Fair Value | |||||||||||||||
| As of December 31, 2025 | Amount | Interest | Amount | Amount | Leveling | |||||||||||||
| Baker Notes(1)(2) | $ | $ | - | $ | $ | Level 3 | ||||||||||||
| Adjuvant Notes(3) | N/A | N/A | ||||||||||||||||
| Exchanged SSNs(1) | - | Level 3 | ||||||||||||||||
| Aditxt Notes(1) | - | Level 3 | ||||||||||||||||
| Totals | $ | $ | $ | $ | N/A | |||||||||||||
| (1) | |
| (2) | |
| (3) | |
| (4) |
| 20 |
| Table of Contents |
The following tables summarize the Company’s derivative liabilities as of September 30, 2026 and December 31, 2025 as discussed in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit (in thousands):
Schedule of Fair Value of Derivative Liabilities
| Fair Value | ||||||||||
| September 30, 2026 | December 31, 2025 | Leveling | ||||||||
| Purchase rights | $ | $ | Level 3 | |||||||
| Total derivative liabilities | $ | $ | ||||||||
Change in Fair Value of Level 3 Financial Liabilities
The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes, Exchanged SSNs, and Aditxt Notes measured at fair value on a recurring basis for the three and nine months ended September 30, 2026 (in thousands):
Schedule of Change in Fair Value of Level 3 Financial Liabilities
| Baker Notes (Assigned to Future Pak; Note 4) | Total Exchanged SSNs and | Total | ||||||||||
| Balance at June 30, 2026 | $ | $ | $ | |||||||||
| Payments | ( | ) | - | ( | ) | |||||||
| Exercises | ||||||||||||
| Change in fair value presented in the condensed consolidated statements of operations | ||||||||||||
| Extinguishment/conversion | - | ( | ) | ( | ) | |||||||
| Balance at issuance | - | |||||||||||
| Change in fair value presented in the condensed consolidated statement of comprehensive operations | ( | ) | ( | ) | ( | ) | ||||||
| Balance at September 30, 2026 | $ | $ | $ | |||||||||
| Baker Notes (Assigned to Future Pak; Note 4) | Total Exchanged SSNs and | Total | ||||||||||
| Balance at December 31, 2025 | $ | $ | $ | |||||||||
| Payments | ( | ) | - | ( | ) | |||||||
| Extinguishment/conversion | - | ( | ) | ( | ) | |||||||
| Balance at issuance | - | |||||||||||
| Change in fair value presented in the condensed consolidated statement of comprehensive operations | ( | ) | ( | ) | ( | ) | ||||||
| Balance at September 30, 2026 | $ | $ | $ | |||||||||
The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes, Exchanged SSNs, and Aditxt Notes measured at fair value on a recurring basis for the three and nine months ended September 30, 2025 (in thousands):
Baker Notes (Assigned to Future Pak; Note 4) | Total | Total | ||||||||||
| Balance at June 30, 2025 | $ | $ | $ | |||||||||
| Extinguishment/conversion | - | ( | ) | ( | ) | |||||||
| Payments | ( | ) | - | ( | ) | |||||||
| Change in fair value presented in the condensed consolidated statements of operations | - | |||||||||||
| Change in fair value presented in the condensed consolidated statements of comprehensive operations | - | |||||||||||
| Balance at September 30, 2025 | $ | $ | $ | |||||||||
Baker Notes (Assigned to Future Pak; Note 4) | Total | Total | ||||||||||
| Balance at December 31, 2024 | $ | $ | $ | |||||||||
| Balance at issuance | - | |||||||||||
| Extinguishment/conversion | - | ( | ) | ( | ) | |||||||
| Payments | ( | ) | - | ( | ) | |||||||
| Change in fair value presented in the condensed consolidated statements of operations | - | |||||||||||
| Change in fair value presented in the condensed consolidated statements of comprehensive operations | ||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | |||||||||
| 21 |
| Table of Contents |
The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2026 (in thousands):
| Purchase Rights | Derivative Liabilities Total | |||||||
| Balance at June 30, 2026 | $ | $ | ||||||
| Change in fair value presented in the condensed consolidated statements of operations | ( | ) | ( | ) | ||||
| Balance at September 30, 2026 | $ | $ | ||||||
| Purchase Rights | Derivative Liabilities Total | |||||||
| Balance at December 31, 2025 | $ | $ | ||||||
| Change in fair value presented in the condensed consolidated statements of operations | ||||||||
| Balance at September 30, 2026 | $ | $ | ||||||
The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2025 (in thousands):
| Purchase Rights | Derivative Liabilities Total | |||||||
| Balance at June 30, 2025 | $ | $ | ||||||
| Change in fair value presented in the condensed consolidated statements of operations | ||||||||
| Balance at September 30, 2025 | $ | $ | ||||||
| Purchase Rights | Derivative Liabilities Total | |||||||
| Balance at December 31, 2024 | $ | $ | ||||||
| Beginning balance | $ | $ | ||||||
| Exercises | ( | ) | ( | ) | ||||
| Change in fair value presented in the condensed consolidated statements of operations | ( | ) | ( | ) | ||||
| Balance at September 30, 2025 | $ | $ | ||||||
| Ending balance | $ | $ | ||||||
Valuation Methodology
Baker Notes
The
fair value of the Baker Notes is determined using a Monte Carlo simulation-based model and is subject to uncertainty due to the assumptions
used in the model. The fair value of the Baker Notes is sensitive to these estimated inputs made by management that are used in the calculation.
The Monte Carlo simulation takes into account several embedded features, factors and management inputs, including the exercise of the
repurchase rights, the Company’s future revenues, meeting certain debt covenants, the maturity term of the note and dissolution.
For the dissolution scenario, the cost approach, an adjusted net asset value method was used to determine the net recoverable value of
the Company, including an estimate of the fair value of the Company’s intellectual property. The estimated fair value of the Company’s
intellectual property was valued using a relief from royalty method which required management to make significant estimates and assumptions
related to forecasts of future revenue, and the selection of the royalty (
Exchanged SSNs and Aditxt Notes
The
fair value of the Exchanged SSNs and Aditxt Notes issued, as described in Note 4 – Debt, were determined by estimating the fair
value of the Market Value of Invested Capital (MVIC) of the Company on a going-concern basis. This was estimated using a form of the
market approach where comparable market revenue multiples were selected and applied to the Company’s forward revenue forecast to
ultimately derive a MVIC indication. In addition, the Company considered a transaction in which certain of its investors sold a portion
of their notes to HUB, as described in Note 4 – Debt. Because the referenced transaction was for only a portion of the Exchanged Notes, the Company did not rely on the full transaction value as a direct indicator of fair value; rather, the implied
value from the transaction was weighted and used as a corroborating market price indicator in support of the MVIC and related inputs
described below. An option pricing model (OPM) was then applied to value the Exchanged SSNs by allocating the estimated MVIC through
the Company’s capital structure including the more senior notes payoff in a hypothetical exit event. Under the OPM, each debt or
equity class is modeled as a call option with a distinct claim on the total value of the Company. The option’s exercise price is
based on the Company’s total value available for each participating security holder. By constructing a series of options in which
the exercise price is set at incremental levels of value, which correspond to the value necessary for each level of debt or equity to
participate, the Company determined the incremental option value of each series. When multiplied by the percentage of ownership of each
class participating, the result is the incremental value allocated to each class under that series. The key unobservable inputs used
in the valuation include the revenue based multiple ranging from 3.10x to 3.60x, a risk-free rate of
| 22 |
| Table of Contents |
Purchase Rights
The Purchase Rights are recorded as derivative liabilities in the condensed consolidated balance sheets. The Purchase Rights are valued using an OPM, such as a Black-Scholes option pricing model, with changes in the fair value being recorded in the condensed consolidated statements of operations. In addition, the Company considered a transaction in which certain of its investors sold a portion of their Purchase Rights to HUB, as described in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit. The Company applied a similar method in consideration of the implied value from the transaction used for Exchanged SSNs and Aditxt Notes. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the MVIC, the cumulative equity value of the Company as a proxy for the exercise price and the expected term the Purchase Rights will be held prior to exercise and a risk-free interest rate. The key unobservable inputs used in the valuation of the Purchase Rights were the same as those used for the Exchanged SSNs and Aditxt Notes as described herein.
Warrants
Warrants are classified as equity and the Company re-evaluates the classification of its warrants at the close of each reporting period to determine their proper balance sheet classification. The warrants are valued using an OPM based on the applicable assumptions, which include the exercise price of the warrants, time to expiration, expected volatility of our peer group, risk-free interest rate, and expected dividends. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the MVIC, the cumulative equity value of the Company as a proxy for the exercise price, the expected term the warrants will be held prior to exercise, a risk-free interest rate, and probability of change of control event. Additionally, because the warrants are re-priced under certain provisions in the agreements, at each re-pricing event the Company must value the warrants using a Black-Scholes option pricing model immediately prior to and immediately following the re-pricing event. The incremental fair value is recorded as an increase to accumulated deficit and additional paid-in capital, in accordance with ASC 470. The key unobservable inputs used in the valuation of warrants were the same as those used the Exchanged SSNs and Aditxt Notes as described aforementioned.
SOLOSEC Asset Acquisition Intangible Asset and Contingent Liabilities
The
total consideration for the SOLOSEC asset acquisition included an up-front payment (paid at closing), sales-based payments to be paid
over
The fair value of the total consideration, including cash paid and future sales-based payments, is determined using a Monte Carlo simulation model, which assumes the Company’s revenue follows a geometric Brownian motion. Using specific revenue factors, including expected growth, risk adjustments, and revenue volatility, future revenues were simulated through the Earnout Term to assess whether sales-based payments would be triggered in each relevant period, as stipulated by the SOLOSEC Asset Purchase Agreement. The average output of the Monte Carlo simulations for each period provides the expected payment value, which is then discounted to its present value to derive the fair value of future sales-based payments and recorded as contingent liabilities. The discount rate is a market index rate based on the Company’s credit risk.
| 23 |
| Table of Contents |
The
fair value of the SOLOSEC contingent liabilities is subject to uncertainty due to the assumptions made by management that are used in
the Monte Carlo simulation-based model. These factors include the estimated future SOLOSEC net revenue, the risk-neutral revenue calculation
and simulation assumptions, payment timing, and the discount rate. The key unobservable inputs used in the valuation include a risk-free
rate of
The fair value of the SOLOSEC contingent liabilities will be updated at each reporting period using the methodology described above. Any changes to the fair value will be recorded as an adjustment to the carrying value of both the contingent liabilities and the SOLOSEC IP intangible asset as per ASC 323, Investments – Equity Method and Joint Ventures (ASC 323). Periodic intangible amortization will also be prospectively updated based on the new fair value of the SOLOSEC IP.
7. Commitments and Contingencies
SOLOSEC Asset Acquisition and Contingent Liabilities
The Company reviewed the SOLOSEC acquisition in accordance with ASC 805, Business Combinations (ASC 805), including applying the screen test. In accordance with ASC 805, the Company engaged a third-party valuation specialist to estimate the fair value for the SOLOSEC IP as well as for the total consideration. Per the valuation, the fair value of the SOLOSEC IP exceeded 90% of the total consideration, which indicates that the screen test failed. Further, the Company did not acquire any substantive processes, which indicates that the acquisition is an asset acquisition rather than a business combination. The Company recorded the fair value of the future sales-based payments as contingent liabilities in accordance with ASC 450, Contingencies (ASC 450) and the fair value of the total consideration plus the transaction costs as an intangible asset in accordance with ASC 350, Intangibles (ASC 350).
Per
the Transition Services Agreement (TSA) entered into in conjunction with the SOLOSEC asset acquisition, the Company expected to purchase
finished goods inventory from the seller at a pre-defined price through the earlier of November 2026 or when the Company provides 10
business days’ notice of termination. The total expected purchase was approximately $
As
of December 31, 2025, the Company expected to purchase up to approximately $
The
TSA also required the seller to provide transitional support services until the Company fully established SOLOSEC operations; the Company
was obligated to pay an immaterial amount quarterly for these services. The Company is also obligated to pay a quarterly royalty, in
amounts equal to a certain percentage of the SOLOSEC net revenue from U.S. sales, beginning July 14, 2024. There are
| 24 |
| Table of Contents |
Fleet Lease
In
December 2019, the Company and Enterprise FM Trust (the Lessor) entered into a Master Equity Lease Agreement whereby the Company leases
vehicles to be delivered by the Lessor from time to time with various monthly costs depending on whether the vehicles are delivered for
a term of
The Company determined that the leased vehicles are accounted for as operating leases under ASC 842, Leases (ASC 842).
Supplemental financial statement information is disclosed in the tables below:
Schedule of Lease Cost
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| Lease Cost (in thousands) | Classification | 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating lease expense | Research and development | $ | - | $ | $ | $ | ||||||||||||
| Operating lease expense | Selling and marketing | |||||||||||||||||
| Operating lease expense | General and administrative | |||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||||
Schedule of Lease Term and Discount Rate
| Lease Term and Discount Rate | September 30, 2026 | December 31, 2025 | ||||||
| Weighted Average Remaining Lease Term (in years) | ||||||||
| Weighted Average Discount Rate | % | % | ||||||
Schedule of Operating Lease Maturities
| Maturity of Operating Lease Liabilities (in thousands) | September 30, 2026 | |||
| Remainder of 2026 (3 months) | $ | |||
| Year ending December 31, 2027 | ||||
| Total lease payments | ||||
| Less imputed interest | ( | ) | ||
| Total | $ | |||
Schedule of Supplement Cash Outflows in Operating Leases
| Other information (in thousands) | 2026 | 2025 | ||||||
| Nine Months Ended September 30, | ||||||||
| Other information (in thousands) | 2026 | 2025 | ||||||
| Operating cash outflows in operating leases | $ | $ | ||||||
| Non-cash addition to ROU assets and lease liabilities due to new leases | $ | - | $ | |||||
| 25 |
| Table of Contents |
Related Party Transactions
Aditxt Notes and Warrants
The
Company determined that Aditxt is a related party based on its beneficial ownership and rights associated with its Series F-1 Shares,
convertible notes, and warrants. As discussed in Note 4 – Debt, on April 8, 2025 and June 26, 2025, the Company entered into two
securities purchase agreements with Aditxt (the Aditxt Notes), pursuant to which the Company issued
senior subordinated convertible notes in the aggregate original principal amount of $
Adjuvant
Because Adjuvant has significant voting power due to its increased beneficial ownership limitation, the Company evaluated the relationship between the entities and determined that Adjuvant is a related party of the Company. Except for the exchange from the Adjuvant Notes to Series G-1 Shares as described in Note 8 – Convertible and Redeemable Preferred Stock and Stockholders’ Deficit, the Adjuvant Fourth Amendment and the Adjuvant Fifth Amendment, each as described and defined in Note 4 – Debt, no other transactions occurred between the two entities in 2025 or through September 30, 2026.
Contingencies
From time to time the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. As of September 30, 2026, there were no other claims or actions pending against the Company which management believes have a probable, or a reasonably possible, probability of a significant unfavorable outcome other than the TherapeuticsMD, Inc. (TherapeuticsMD) dispute as described below.
During
the nine months ended September 30, 2025, the Company settled a portion of its trade payables with vendors, which resulted in a $
On
December 14, 2020, a trademark dispute captioned TherapeuticsMD, Inc. v Evofem Biosciences, Inc., was filed in the U.S. District Court
for the Southern District of Florida against the Company, alleging trademark infringement of certain trademarks owned by TherapeuticsMD
under federal and state law (Case No. 9:20-cv-82296). On July 18, 2022, the Company settled the lawsuit with TherapeuticsMD, with certain
requirements which were required to be performed by July 2024 (the Settlement Timeline), including changing the name of PHEXXI. The Company
failed to meet the terms of the settlement agreement by the Settlement Timeline. As a result, the Company is currently working with TherapeuticsMD
on resolution of this issue. In September 2024, the Company filed an application for a new name – PHEXX – which was approved
by the FDA in April 2025. In accordance with ASC 450, the Company has accrued the present value of the probable settlement amounts remaining
payable over the next several years, which was $
As of September 30, 2026, the Company has received multiple letters from purported Company stockholders demanding that the Company’s board of directors take action on behalf of the Company to remedy allegations regarding the Company’s disclosures to shareholders with respect to various alleged omissions of material information in both its preliminary proxy statement filed September 23, 2024 and definitive proxy statement filed September 8, 2025 relating to the Amended and Restated Merger Agreement with Aditxt, as amended, and demands made under Section 220 of the DGCL for books and records related to the transaction and disclosures in the proxy statement. The Company believes all such demands are without merit and the proposed merger was terminated without penalty on October 20, 2025.
| 26 |
| Table of Contents |
On
September 27, 2024, Future Pak, LLC, as agent for the purchasers (in such capacity, the Future Pak Designated Agent) provided a Notice
of Event of Default and Reservation of Rights (the Notice of Default) relating to the Baker Bros. Purchase Agreement, as amended, by
and among the Company, Designated Agent, as certain guarantors, and the purchasers. The Notice of Default claims that by entering into
arrangements to repay certain existing obligations, including obligations owed to the U.S. Department of Health and Human Services, an
Event of Default has occurred under Section 9.1(e) of the Baker Bros. Purchase Agreement.
On October 27, 2024, the Future Pak Designated Agent sent an amended and supplemented notice to the Notice of Default which adds additional claims of default based on the Company’s current repayment agreements of existing obligations, including obligations owed to the U.S. Department of Health and Human Services, an Event of Default has occurred under Section 9.1(e) of the Baker Bros. Purchase Agreement. Furthermore, the Amended Notice stated that, because the events of default described in the Amended Notice of Default are not the certain prior events of default listed in the Forbearance Agreement (the Specified Defaults), the Future Pak Designated Agent and the holders of the senior secured promissory notes described in the Baker Bros. Purchase Agreement thereby provided notice to the Company that the Forbearance Agreement is terminated as of October 27, 2024.
On
November 8, 2024, the Future Pak Designated Agent sent an amended and supplemented notice to
The Company strongly disagrees with the Future Pak Designated Agent’s claim that any Event of Default has occurred. The Company intends to vigorously contest any attempt by the Future Pak Designated Agent and the purchasers to exercise their default rights and remedies under the Baker Bros. Purchase Agreement.
Intellectual Property Rights
In
2014, the Company entered into an amended and restated license agreement (the Rush License Agreement) with Rush University Medical Center
(Rush University), pursuant to which Rush University granted the Company an exclusive, worldwide license of a patent and certain know-how
related to its vaginal pH modulator technology (US6706276, the Rush Patent). Pursuant to the Rush License Agreement, until the expiration
of the Rush Patent, the Company was obligated to pay Rush University an earned royalty during the patent term, calculated as a mid-single
digit percentage of PHEXX net sales (the Rush Royalty). In September 2020, the Company entered into the first amendment to the Rush License
Agreement, pursuant to which the Company agreed to pay a minimum annual royalty amount of $
The Rush Patent would expire on March 6, 2021 (the Original Expiration Date) if no PTE was obtained. Rush University filed an application for PTE in July 2020, which would extend the expiration date of the Rush Patent to March 6, 2026 if granted. Multiple Orders Granting Interim Extension (OGIEs) were received from the U.S. Patent and Trademark Office (USPTO) while the PTE was under evaluation. The last OGIE expired on March 6, 2025.
Because
the USPTO had granted multiple OGIEs to Rush University, between the date of the original PTE application (July 2020) and the final OGIE
expiration (March 2025), the Company determined it was probable that the PTE extending the expiration to March 6, 2026 would be granted.
Therefore, the Company accrued a total of $
During
the first quarter of 2025, the Company’s legal counsel ascertained that no further OGIEs were granted after March 6, 2025 and the
PTE had also still not been granted. The Company discontinued accruing the Rush Royalty since, based on the new information, the Company
deemed it remote that the PTE would ultimately be granted. Amounts previously accrued under the Rush License Agreement were still being
assessed at that time and as such, no adjustments were made.
| 27 |
| Table of Contents |
Furthermore,
in August 2025 the FDA confirmed that the relevant active ingredient covered by the Rush Patent had previously been used in other FDA-approved
products and, as such, no PTE should be granted. The Company and its legal counsel determined that the Rush Patent expired on the Original
Expiration Date and as such it is no longer probable that the Company will be required to pay any expenses related to the Rush Royalty
accrued after that date. The Company reversed the outstanding accrued Rush Royalty contingent liability of $
If
the Company determines to pursue a refund of the estimated royalties paid but not earned per its current analysis, it could potentially
receive a refund of $
Our vaginal pH modulator (PHEXX) remains protected in the U.S. by four Orange Book patents which are solely-owned by Evofem.
Other Contractual Commitments
In
November 2019, the Company entered into a supply and manufacturing agreement with a U.S. based third-party to manufacture PHEXX, in accordance with all applicable current good manufacturing practice
regulations. There were no purchases under the supply and manufacturing agreement for the three months ended September 30, 2026, and
approximately $
On September 17, 2026, the Company entered into a manufacturing agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited, a Hong Kong company organized and existing under the laws of Hong Kong and Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited., a company organized under the laws of the People’s Republic of China (together, Zhaoke), pursuant to which Zhaoke agreed to manufacture and supply PHEXX in accordance with all applicable current good manufacturing practice regulations. Development and validation work is underway; there have been no purchases under this manufacturing agreement to date.
8. Convertible and Redeemable Preferred Stock and Stockholders’ Deficit
Warrants
In
May 2022, the Company completed an underwritten public offering (the May 2022 Public Offering) which included the issuance of common
warrants to purchase
In
June 2022, as required by the First Baker Amendment, the Company issued the June 2022 Baker Warrants to purchase up to
In
February, March, April, July, August, and September 2023, pursuant to the Exchanged SSNs as discussed in Note 4 – Debt, the Company
issued warrants to purchase up to
| 28 |
| Table of Contents |
As
of September 30, 2026, warrants to purchase up to
Schedule of Warrants
| Type of Warrants | Underlying Common Stock to be Purchased | Exercise Price | Issue Date | Exercise Period | ||||||||
| Common Warrants | $ | January 13, 2022 | ||||||||||
| Common Warrants | $ | March 1, 2022 | ||||||||||
| Common Warrants | $ | May 4, 2022 | ||||||||||
| Common Warrants | $ | May 24, 2022 | ||||||||||
| Common Warrants | $ | June 28, 2022 | ||||||||||
| Common Warrants | $ | December 21, 2022 | ||||||||||
| Common Warrants | $ | February 17, 2023 | ||||||||||
| Common Warrants | $ | March 20, 2023 | ||||||||||
| Common Warrants | $ | April 5, 2023 | ||||||||||
| Common Warrants | $ | July 3, 2023 | ||||||||||
| Common Warrants | $ | August 4, 2023 | ||||||||||
| Common Warrants | $ | September 27, 2023 | ||||||||||
| Common Warrants | $ | April 8, 2025 | ||||||||||
| Common Warrants | $ | June 26, 2025 | ||||||||||
| Prefunded Common Warrants | $ | September 27, 2023 | ||||||||||
| Total | ||||||||||||
Preferred Stock
The Company is authorized to
issue up to
| 29 |
| Table of Contents |
Convertible and Redeemable Preferred Stock
Series E-1 Shares
The
Company has designated
Series F-1 Convertible Preferred Stock
The Company has designated
Series G-1 Convertible Preferred Stock
The Company has designated
Upon specified triggering events, including certain payment defaults, failures to deliver shares upon conversion, trading suspensions, bankruptcy proceedings and certain judgments against the Company, holders may exercise alternative conversion rights based on market-price formulas and applicable redemption premiums, potentially resulting in additional dilution to existing stockholders.
On March 5, 2026, the Company
issued
| 30 |
| Table of Contents |
The fair value of the Series G-1 Shares issued was determined by estimating the fair value of the MVIC of the Company on a going-concern basis. This was estimated using a form of the market approach where comparable market revenue multiples were selected and applied to the Company’s forward revenue forecast to ultimately derive a MVIC indication. An OPM was then applied to value the Series G-1 Shares by allocating the estimated MVIC through the Company’s capital structure including the more senior notes payoff in a hypothetical exit event. Under the OPM, each debt or equity class is modeled as a call option with a distinct claim on the total value of the Company. The option’s exercise price is based on the Company’s total value available for each participating security holder. By constructing a series of options in which the exercise price is set at incremental levels of value, which correspond to the value necessary for each level of equity to participate, we determined the incremental option value of each series. When multiplied by the percentage of ownership of each equity class participating, the result is the incremental value allocated to each class under that series.
During the three and nine months ended September 30, 2026, the Company recognized deemed dividends of approximately $
Common Stock
As of September 30, 2026, the Company was authorized to issue
Purchase Rights
The Company has outstanding
Purchase Rights issued pursuant to exchange agreements entered into with certain holders of its convertible notes, which entitle holders
to receive shares of Common Stock. The Purchase Rights had an aggregate value of $
On June 29, 2026 and on July 2, 2026, HUB acquired a portion of the Purchase Rights from certain original holders. The Company was not involved in the transactions and did not receive any remuneration as part of the transactions. The portion of the Purchase Rights that were sold to HUB have the same terms and maturity date as the initial Purchase Rights, and all Purchase Rights continue to qualify as derivative liabilities and will be adjusted to fair value at each reporting date.
| 31 |
| Table of Contents |
Common Stock Reserved for Future Issuance
As of September 30, 2026, the Company had reserved the following shares of Common Stock for future issuance:
Summary of Common Stock Reserved for Future Issuance
| Common Stock issuable upon the exercise of stock options outstanding | ||||
| Common Stock issuable upon the exercise of Common Stock warrants | ||||
| Common Stock available for future issuance under the 2019 ESPP | ||||
| Common Stock available for future issuance under the Inducement Plan | ||||
| Common Stock available for future issuance under the 2025 Plan | ||||
| Common Stock reserved for the exercise of purchase rights | ||||
| Common Stock reserved for the conversion of convertible notes | ||||
| Common Stock reserved for the conversion of series E-1 preferred stock | ||||
| Common Stock reserved for the conversion of series G-1 preferred stock | ||||
| Total Common Stock reserved for future issuance(1) |
| (1) |
9. Stock-based Compensation
Equity Incentive Plans
Schedule of Stock-based Compensation Expense Related to Stock Options
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Research and development | $ | - | $ | - | $ | - | $ | |||||||||
| Selling and marketing | - | |||||||||||||||
| General and administrative | - | |||||||||||||||
| Total | $ | - | $ | $ | $ | |||||||||||
Stock Options
There
were
10. Subsequent Events
The Company’s management has evaluated subsequent events after the unaudited consolidated balance sheet dated as of September 30, 2026, through the date of filing of this Quarterly Report. Based upon the evaluation, management has determined that, other than as disclosed herein, no subsequent events have occurred that would require recognition in the accompanying condensed consolidated financial statements or disclosure in the notes thereto.
Fifth Amendment of Adjuvant Notes
On October 9, 2026, the Company and the Adjuvant Purchasers entered into a fifth amendment to the Adjuvant Purchase Agreement (the Adjuvant Fifth Amendment). The Adjuvant Fifth Amendment amends certain provisions including updating the date that the Adjuvant Notes will be payable in full to the earlier of (a) December 1, 2026, (b) at the election of Adjuvant, the date of a consummation of a Change of Control (as defined in the Adjuvant Purchase Agreement), and (c) the date of any acceleration of the Adjuvant Notes in accordance with Section 8 (the maturity date, as per the Adjuvant Purchase Agreement). The Adjuvant Notes may not be prepaid prior to December 1, 2026 without prior written consent of the Adjuvant Purchasers.
| 32 |
| Table of Contents |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The terms “we,” “us,” “our,” “Evofem” or the “Company” refer collectively to Evofem Biosciences, Inc. and its wholly-owned subsidiaries, unless otherwise stated. All information presented in this quarterly report on Form 10-Q (Quarterly Report) is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months, or periods refer to our fiscal years ending December 31 and the associated quarters, months, and periods of those fiscal years.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report. Some of the information contained in this discussion and analysis is set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.
Overview
We are a San Diego-based commercial-stage biopharmaceutical company with a strong focus on innovation in women’s health. We currently commercialize two FDA-approved products: PHEXX® (lactic acid, citric acid and potassium bitartrate) vaginal gel and SOLOSEC® (secnidazole) 2 g oral granules.
Approved by the FDA on May 22, 2020, PHEXX is the first and only non-hormonal prescription contraceptive gel. It is locally acting, with no systemic activity, and used on-demand by women only when they have sex. Because PHEXX is a non-hormonal contraceptive, it is not associated with side effects of exogenous hormone use. In some women, these side effects may include depression, weight gain, headaches, loss of libido, mood swings and irritability. Taking hormones may not be right for some women, especially those with certain medical conditions, including clotting disorders hormone-sensitive cancer, diabetes, or a BMI over 30, or those who are breast feeding or who smoke. Per the National Center for Health Statistics (NCHS), more than 15.9 million women in the U.S. will not use a hormonal contraceptive.2
Evofem delivered PHEXX net sales growth in each consecutive year since it was launched in September 2020 through December 2025. Key growth drivers include social media campaigns, participation in strategic medical conferences, and initiatives to expand use of PHEXX in women who take oral birth control pills in conjunction with GLP-1 prescription medications like Mounjaro and Zepbound for weight loss. These drugs may make oral birth control pills less effective at certain points in the dosing schedule. Per the products’ USPIs, prescribers are instructed to “advise patients using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method” to prevent unintended pregnancy during these times.
In July 2024, we acquired global rights to SOLOSEC. This FDA-approved single-dose oral antimicrobial agent provides a complete course of therapy for the treatment of two common sexual health infections – bacterial vaginosis (BV) and trichomoniasis (Trich). The SOLOSEC acquisition aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. We expect commercialization of SOLOSEC will benefit from our commercial infrastructure and strong physician relationships.
We intend to expand the global reach of our products and further increase our global potential through ex-U.S. partnerships or licensing agreements for PHEXX and SOLOSEC.
We licensed exclusive commercial rights for PHEXX in MENA to Pharma 1 Drug Store, an emerging Emirati health care company. Under the License and Supply Agreement dated on July 17, 2024, as amended on May 3, 2025, the licensed territory includes the UAE, Kuwait, Saudi Arabia, Qatar, Oman, and Jordan, with potential to expand into 15 other countries in the region. Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell PHEXX, and will handle all aspects of distribution, sales and marketing, pharmacovigilance and all other commercial functions in these countries. Evofem will supply product to Pharma 1 at cost-plus. Pharma 1 filed for regulatory approval of PHEXX in the UAE in June 2025. The Emirates Drug Establishment issued favorable pricing certificates for PHEXX in late 2025.
2 Daniels K and Abma J. Current Contraceptive Status Among Females Ages 15–49: United States, 2022–2023. NCHS Data Brief No. 539. August 2025. Data table for Figure 1, sourced from National Survey of Family Growth (NSFG) 2022–2023. https://www.cdc.gov/nchs/data/databriefs/db539.pdf
| 33 |
| Table of Contents |
The Company licensed commercial rights for SOLOSEC in MENA to Pharma 1 on May 19, 2025. Under this agreement, the licensed territory includes the UAE, Kuwait, Saudi Arabia, Qatar, Oman, and Jordan, with potential to expand into 15 other countries in the region. Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell SOLOSEC, and will handle all aspects of distribution, sales and marketing, pharmacovigilance and all other commercial functions in these countries. Evofem will supply product to Pharma 1 at a specified cost per unit. Pharma 1 filed for regulatory approval of SOLOSEC in the UAE in September 2025.
On April 24, 2026, we entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (Clovis Davis), to commercialize SOLOSEC in Sub-Saharan Africa (the Territory) for a period of five years commencing on April 24, 2026. Under the distributorship agreement, Clovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory. Local regulatory filings for approval of SOLOSEC will be based on Evofem’s registration dossier submitted and approved by the FDA. Regulatory work is underway for SOLOSEC in Uganda, the first planned market under this agreement.
Under the 2020 Global Health Agreement with Adjuvant Capital, the Company submitted marketing applications for PHEXX under the trademark Femidence™ in Nigeria, Ethiopia, and Ghana. Femidence was approved in Nigeria on October 6, 2022, by the National Agency for Food and Drug Administration and Control. In October 2021, the Company submitted Femidence for approval in Mexico. The Company has not allocated resources to follow up with these regulatory bodies or advance commercialization in Nigeria due to fiscal constraints since October 2022.
We halted clinical development of our investigational product candidates in October 2022 to focus resources on growing domestic sales of PHEXX for the prevention of pregnancy.
In the second quarter of 2025, enrollment commenced in an investigator-led randomized, open-label, parallel Phase 4 clinical trial to evaluate the efficacy and cost-effectiveness of secnidazole (SOLOSEC® 2 g, one dose administered one time) versus metronidazole (Flagyl® 500 mg, administered twice daily for seven days) for the treatment of Trich in men and women. Study investigators hypothesize that, in the current clinical trial, the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC arm versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection. This trial is funded directly by the National Institutes of Health (NIH).
In an investigator-led clinical study of SOLOSEC in 24 women with recurrent bacterial vaginosis (BV), once-weekly dosing with SOLOSEC demonstrated efficacy matching or potentially surpassing outcomes of current CDC-recommended suppressive treatments. These promising results underscore SOLOSEC’s potential to redefine the standard of care for recurrent BV – offering a simpler treatment option for long-term symptom control. The study was presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.
PHEXX as a Contraceptive; Commercial Strategies
In September 2020, we commercially launched PHEXX in the United States. Our sales force promotes PHEXX directly to obstetrician/gynecologists (OB/GYNs) and their affiliated health professionals, who collectively write the majority of prescriptions for contraceptive products. Our sales force comprises regional sales representatives, sales managers, business directors, and a Vice President of Commercial Operations. Additionally, we offer women direct access to PHEXX via a telehealth platform. Using this platform, women can directly meet with an HCP to determine their eligibility for a PHEXX prescription and, if eligible, have the prescription written by the HCP, then filled and mailed directly to them by a third-party pharmacy.
Our comprehensive commercial strategy for PHEXX includes marketing and product awareness campaigns targeting HCPs and women of reproductive potential in the U.S., including the approximately 15.9 million women who are not using hormonal contraception and the approximately 10.3 million women who are using a short-acting hormonal contraceptive, some of whom, particularly oral birth control pill users, may be ready to move to an FDA-approved, non-invasive, non-systemic hormone-free contraceptive, as well as certain identified target HCP segments.3 In addition to marketing and product awareness campaigns, our commercial strategy includes payer outreach and execution of our consumer digital and media strategy.
3 Daniels K and Abma J. Current Contraceptive Status Among Females Ages 15–49: United States, 2022–2023. NCHS Data Brief No. 539. August 2025. Data table for Figure 1, sourced from National Survey of Family Growth (NSFG) 2022–2023. https://www.cdc.gov/nchs/data/databriefs/db539.pdf
| 34 |
| Table of Contents |
We continue working to increase the number of lives covered and to gain a preferred formulary position for PHEXX.
Previous contracting efforts have validated our access strategy. With PHEXX approval rates consistently above 80%, the Company has shifted from broad payer contracting to strengthening pharmacy partnerships. In 2025, we expanded our network in two of our highest-volume markets — California and the Northeast — by adding new partners in California and a regional distributor with more than 90 pharmacies in the Northeast. These targeted partnerships address high-demand areas, improving patient access while supporting more cost-effective and scalable pull-through.
Approximately 13.7 million lives are covered under our December 2020 contract award from the U.S. Department of Veterans Affairs.
We also participate in government programs, including the 340B and the Medicaid Drug Rebate Program. As a result of our participation in the Medicaid National Drug Rebate Program, the U.S. Medicaid population gained access to PHEXX on January 1, 2021. As of June 2026, Medicaid provides health coverage to approximately 66.0 million members; nearly two-thirds of adult women enrolled in Medicaid are in their reproductive years (19-44). Additionally, we began participating in a 340B Group Purchasing Organization (GPO) that serves safety-net clinics throughout the U.S. in June 2024. This GPO has over 6,500 members, which expands our reach among safety-net providers.
PHEXX is classified in the databases and pricing compendia of Medi-Span and First Databank, two major drug information databases that payers can consult for pricing and product information, as the first and only “Vaginal pH Modulator.”
Effective as of January 1, 2023, most insurers and PBMs must provide coverage, with no out-of-pocket costs (e.g., $0 copay) to the subscriber or dependent, for FDA-approved contraceptive products, like PHEXX, prescribed by healthcare providers.
To comply with these federal guidelines, payers are increasingly covering PHEXX by:
| – | Adding PHEXX to formulary (commercial insurers) or preferred drug list (Medicaid) | |
| – | Removing the requirement for a Prior Authorization letter from the HCP (commercial insurers) | |
| – | Moving PHEXX to $0 copay (commercial insurers) |
In 2022, Evofem developed and introduced a new contraceptive educational chart for patients and HCPs that details high-level information about birth control methods currently available to women in the U.S., including the vaginal pH modulator.
| 35 |
| Table of Contents |
SOLOSEC
In July 2024, we expanded our commercial portfolio by acquiring global rights to SOLOSEC® (secnidazole) 2 g oral granules, a single-dose oral antimicrobial agent that provides a complete course of therapy with just one dose for the treatment of two common sexual health infections. SOLOSEC is FDA-approved for the treatment of:
| 1) | Bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and | |
| 2) | Trichomonas vaginalis (Trich), a common sexually transmitted infection (STI), in people 12 years of age and older. |
SOLOSEC has the same call point as PHEXX, enabling us to leverage our commercial infrastructure and strong physician relationships. We re-launched the brand in November 2024.
Bacterial Vaginosis
Bacterial vaginosis (BV) affects an estimated 21 million women in the U.S., approximately 29% of the U.S. population, making it the most common vaginal condition in women ages 15-44. It results from an overgrowth of bacteria, which upsets the balance of the natural vaginal microbiome and can lead to symptoms including odor and discharge. Of interest, BV raises the pH of the vagina, making it a more friendly environment for Trich and other STIs; approximately 20% of BV patients also have Trich.
If left untreated, BV can have serious health consequences. Untreated or improperly treated BV is associated with increased risk of infection with STIs like HPV, herpes, Trich, chlamydia, gonorrhea, and HIV, as well as transmission of STIs to a partner. Additional risks include developing pelvic inflammatory disease (PID), which can threaten a woman’s fertility, and complications with gynecological surgery.
In May 2025, an investigator-led clinical trial entitled ‘Once Weekly Secnidazole Granules for the Treatment of Recurrent Bacterial Vaginosis’ was presented at the 2025 ACOG Annual Clinical and Scientific Meeting; the abstract was subsequently published in Obstetrics & Gynecology. In this focused clinical study of 24 women with recurrent BV, once-weekly dosing with SOLOSEC demonstrated efficacy matching or potentially surpassing outcomes of current CDC-recommended suppressive treatments. These promising results underscore SOLOSEC’s potential to redefine the standard of care for recurrent BV by offering a simpler treatment option for long-term symptom control.
Trichomoniasis
Trichomoniasis (Trich) is the most common non-viral STI in the world. It is caused by a parasite called Trichomonas vaginalis and affects both women and men. All sexual partners of an infected person must be treated to prevent reinfection with the parasite. In 2018, there were an estimated 6.9 million new T. vaginalis infections in the U.S. According to the CDC, the U.S. prevalence of T. vaginalis is 2.1% among females and 0.5% among males, with the highest rates among Black females (9.6%) and Black males (3.6%). A study of STD clinic attendees in Birmingham, Alabama, identified a prevalence of 27% among women and 9.8% among men. Approximately 70% of women with Trich are also infected with the bacteria that cause BV.
In clinical trials, a single dose of SOLOSEC demonstrated a cure rate of 92.2% for Trich in women, while reported cure rates in males range from 91.7%-100%.
SOLOSEC’s one-and-done dosing and the resulting high level of compliance is believed to be a significant differentiator. Non-compliance to a multi-day metronidazole regimen is a contributing factor to persistent Trich or BV; both ACOG and the CDC no longer recommend single dose metronidazole to treat Trich in women.
A Phase 4 investigator-led randomized, open-label, parallel arm clinical trial is underway to evaluate the efficacy and cost-effectiveness of secnidazole (SOLOSEC 2 g, one dose administered one time) versus metronidazole (Flagyl® 500 mg, administered twice daily for seven days) for the treatment of Trich in men and women. Study investigators hypothesize that, in the current clinical trial, the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC arm versus the multi- dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection. This trial is directly funded by the National Institutes of Health (NIH).
| 36 |
| Table of Contents |
Financial Operations Overview
Net Product Sales
Our revenue recognition is based on unit shipments to our customers, which consist of wholesale distributors, retail pharmacies, telehealth companies, mail-order specialty pharmacies, five sites participating in the Phase 4 NIH-funded clinical trial, and, in the UAE, our licensee, Pharma 1. We have recognized net product sales in the U.S. since the commercial launch of PHEXX in September 2020; SOLOSEC net product sales were added to our revenue beginning in July 2024. Gross revenues, as discussed in Note 3 - Revenue, are adjusted for variable consideration, including our patient support programs.
Cost of Goods Sold
Inventory costs include all purchased materials, direct labor, and manufacturing overhead. We are obligated to pay quarterly royalties under the SOLOSEC Asset Purchase Agreement dated July 14, 2024; this royalty is based on a percentage of SOLOSEC net sales in the U.S., adjusted for co-pay program costs and is part of the contingent liabilities recorded on the condensed consolidated balance sheet. There are no minimum quarterly or annual royalty amounts. Such royalty costs were immaterial and $0.1 million for the three and nine months ended September 30, 2026, respectively, and were immaterial and $0.1 million for the three and nine months ended September 30, 2025, respectively.
Operating Expenses
Research and Development Expenses
Our research and development expenses primarily consist of costs associated with ongoing improvements related to our products. These expenses include:
| ● | ongoing improvements of manufacturing and analytical efficiency; | |
| ● | ongoing product characterization and process optimization; | |
| ● | alternative raw material evaluation to secure an uninterrupted supply chain and reduce cost of goods sold; | |
| ● | employee-related expenses, including salaries, benefits, travel and noncash stock-based compensation expense; and | |
| ● | facilities, depreciation, and other allocated expenses, which include direct and allocated expenses for rent, depreciation of equipment, and research and other supplies. |
We expense internal and third-party research and development expenses as incurred. We do not anticipate significant investment in clinical development for the foreseeable future.
During the nine months ended September 30, 2025, the Company negotiated a portion of its trade payables with numerous vendors, which resulted in a $5.6 million one-time reduction in research and development expenses.
Selling and Marketing Expenses
Our selling and marketing expenses consist primarily of PHEXX and SOLOSEC commercialization costs, the PHEXX telehealth platform, training, salaries, benefits, travel, noncash stock-based compensation expense, other related costs for our employees and consultants, and the Prescription Drug User Fee Act (PDUFA) fees we are required to pay to the FDA for our products.
| 37 |
| Table of Contents |
General and Administrative Expenses
Our general and administrative expenses consist primarily of salaries, benefits, travel, business development expenses, investor and public relations expenses, noncash stock-based compensation, and other related costs for our employees. Other general and administrative expenses include facility-related costs not otherwise included in research and development or selling and marketing, and professional fees for accounting, auditing, tax and legal fees, and other costs associated with obtaining and maintaining our patent portfolio.
Other Income (Expense)
Other income (expense) consists primarily of interest expense and the fair value adjustments of financial instruments issued in various capital raise transactions, including loss on issuance of financial instruments, change in fair value adjustments, and gains or losses on debt extinguishment. The change in fair value of financial instruments was recognized as a result of mark-to-market adjustments for those financial instruments.
Results of Operations
Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025 (in thousands):
Net Product Sales
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Product sales, net | $ | 4,628 | $ | 4,952 | $ | (324 | ) | (7 | )% | |||||||
The decrease in product sales, net, primarily reflects a decrease in PHEXX units sold as wholesalers have continued to sell through inventory purchased in December 2025, ahead of the January 2026 price increase in the current year. The ongoing absence of funding for marketing and a reduction in filled sales territories in the current quarter also contributed. This was partially offset by an increase in SOLOSEC units sold as well as the increase in WAC and improved gross-to-net realization for both products in the 2026 period.
Cost of Goods Sold
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Cost of goods sold | $ | 750 | $ | 905 | $ | (155 | ) | (17 | )% | |||||||
The decrease in cost of goods sold was primarily due to the decrease in product sales, net.
Gain on Change in Accounting Estimates on Contingent Royalty Liability
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Gain on change in accounting estimates on contingent royalty liability | $ | - | $ | (1,933 | ) | $ | 1,933 | 100 | % | |||||||
The $1.9 million one-time gain on change in accounting estimates on contingent royalty liability in the prior year period was due to the reversal of previously accrued but unpaid amounts related to the Rush Royalty as a result of the additional information obtained during the three months ended September 30, 2025, including clarification by the FDA that no PTE should be granted. See Note 7 – Commitments and Contingencies for more information regarding this reversal.
Amortization of Intangible Asset
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Amortization of intangible asset | $ | 15 | $ | 80 | $ | (65 | ) | (81 | )% | |||||||
The decrease in amortization of intangible asset primarily reflects the decrease in value of the SOLOSEC intangible asset based on the quarterly valuations of the related contingent liabilities. As the asset value decreases, the quarterly amortization also decreases.
Research and Development Expenses
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Research and development, net | $ | 341 | $ | 470 | $ | (129 | ) | (27 | )% | |||||||
The decrease in research and development expenses was primarily due to $0.1 million in outside services related to lower consulting costs.
| 38 |
| Table of Contents |
Selling and Marketing Expenses
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Selling and marketing | $ | 1,534 | $ | 2,391 | $ | (857 | ) | (36 | )% | |||||||
The decrease in selling and marketing expenses was primarily due to a $0.6 million decrease in business development costs due in part to the reversal of $0.3 million in accounts payable settlements as well as reduced spending and a $0.3 million decrease in personnel costs stemming from the decision not to fill two currently open sales territories.
General and Administrative Expenses
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| General and administrative | $ | 1,248 | $ | 2,088 | $ | (840 | ) | (40 | )% | |||||||
The decrease in general and administrative expenses was primarily due to a $0.4 million decrease in personnel costs, a $0.3 million decrease in outside services and professional costs, primarily related to a decrease in expenses related to audit, legal, and consulting fees, as well as a $0.1 million reduction in insurance premiums.
Total Other Income (Expense), Net
| Three Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Total other income (expense), net | $ | 264 | $ | (2,524 | ) | $ | 2,788 | 110 | % | |||||||
Total other income, net, for the three months ended September 30, 2026 primarily included a gain of $1.5 million related to the change in fair value of financial instruments, partially offset by a loss of $0.4 million related to the partial extinguishment and reissuance of the of the Exchanged SSNs acquired by HUB and $0.8 million of interest expense, primarily related to the Adjuvant Note.
Total other expense, net, for the three months ended September 30, 2025 primarily included $0.7 million of interest expense related primarily to the Adjuvant Note and a loss of $1.8 million related to the change in fair value of financial instruments including adjustments related to the purchase rights of $1.1 million and those related to the Baker Notes of $0.7 million. Historically the changes in fair value related to the Baker Notes have been recorded in the condensed consolidated statements of comprehensive operations as the changes were determined to be related to changes in the Company’s credit risk. However, in the three months ended September 30, 2025, the primary driver for the increase in the fair value of the Baker Notes is related to the Company not retiring the notes by September 8, 2025, which caused the total amount legally payable to repurchase the notes to increase by approximately $2.8 million.
| 39 |
| Table of Contents |
Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025 (in thousands):
Net Product Sales
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Product sales, net | $ | 8,160 | $ | 10,622 | $ | (2,462 | ) | (23 | )% | |||||||
The decrease in product sales, net, primarily reflects a decrease in PHEXX units sold, as previously discussed, and the temporary and now-resolved exclusion of PHEXX from certain state Medicaid and public health programs while transitioning to the new NDC number, partially offset by an increase in SOLOSEC units sold, the increase in WAC, and improved gross-to-net realization for both products.
Cost of Goods Sold
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Cost of goods sold | $ | 1,671 | $ | 2,025 | $ | (354 | ) | (17 | )% | |||||||
The decrease in cost of goods sold was primarily due to the decrease in product sales, net, partially offset by a write-off in the current period of $0.3 million of excess SOLOSEC inventory.
Gain on Change in Accounting Estimates on Contingent Royalty Liability
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Gain on change in accounting estimates on contingent royalty liability | $ | - | $ | (1,933 | ) | $ | 1,933 | 100 | % | |||||||
The gain on change in accounting estimates on contingent royalty liability was due to the reversal of previously accrued but unpaid amounts related to the Rush Royalty as a result of the additional information obtained during the three months ended September 30, 2025, including clarification by the FDA that no PTE should be granted. See Note 7 – Commitments and Contingencies for more information regarding this reversal.
Amortization of Intangible Asset
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Amortization of intangible asset | $ | 104 | $ | 410 | $ | (306 | ) | (75 | )% | |||||||
The decrease in amortization of intangible asset primarily reflects the decrease in value of the SOLOSEC intangible asset based on the quarterly valuations of the related contingent liabilities. As the asset value decreases, the quarterly amortization also decreases.
Research and Development Expenses
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Research and development, net | $ | 1,553 | $ | (3,819 | ) | $ | 5,372 | 141 | % | |||||||
| 40 |
| Table of Contents |
During the nine months ended September 30, 2025, the Company settled a portion of its trade payables with numerous vendors, which resulted in a one-time $5.6 million reduction in research and development expenses; such settlement did not recur in the current period. There was also a decrease of facilities and outside services of $0.6 million, partially offset by an increase to personnel costs of $0.3 million due to hiring in-house instead of using more expensive consulting services.
Selling and Marketing Expenses
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Selling and marketing | $ | 5,702 | $ | 7,616 | $ | (1,914 | ) | (25 | )% | |||||||
The decrease in selling and marketing expenses was primarily due to a $1.1 million decrease in business development and distribution costs related to the termination of a commercial rebate program to better align resources with core business priorities and the previously mentioned accounts payables settlements, a $0.6 million decrease in personnel costs, and a $0.2 million decrease related to travel and other expense.
General and Administrative Expenses
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| General and administrative | $ | 5,448 | $ | 6,296 | $ | (848 | ) | (13 | )% | |||||||
The decrease in general and administrative expenses was primarily related to a $0.3 million decrease in outside services and other professional services, a $0.4 million decrease in personnel costs, and a $0.1 million decrease in facilities costs.
Total Other Income (Expense), Net
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Total other income (expense), net | $ | (9,180 | ) | $ | (2,421 | ) | $ | (6,759 | ) | 279 | % | |||||
Total other expense, net, for the nine months ended September 30, 2026 primarily included a loss of $4.4 million related to the change in fair value of financial instruments, a loss of $2.6 million related to the partial extinguishment and reissuance of the of the Exchanged SSNs acquired by HUB, and $2.2 million of interest expense, primarily related to the Adjuvant Note.
Total other expense, net, for the nine months ended September 30, 2025 primarily included a $1.9 million interest expense related to the Adjuvant Note and a loss on the change in fair value of financial instruments of $0.5 million, including a gain related to the purchase rights of $0.2 million and a loss related to the Baker Notes of $0.7 million. Historically the changes in fair value related to the Baker Notes have been recorded in the condensed consolidated statements of comprehensive operations as the changes were determined to be related to changes in the Company’s credit risk. However, in the nine months ended September 30, 2025, the primary driver for the increase in the fair value of the Baker Notes is related to the Company not retiring the notes by September 8, 2025, which caused the total amount legally payable to repurchase the notes to increase by approximately $2.8 million.
Liquidity and Capital Resources
Overview
As of September 30, 2026, we had a working capital deficit of $78.8 million and an accumulated deficit of $913.2 million. We have financed our operations to date primarily through the issuance of preferred stock, Common Stock, warrants and convertible and term notes; cash received from private placement transactions; and, to a lesser extent, product sales. As of September 30, 2026, we had approximately $0.3 million comprised entirely of restricted cash and cash equivalents available for use as prescribed in the Adjuvant Notes (as defined in Note 4 - Debt). Our restricted cash and cash equivalents include amounts held in checking accounts. Management believes that the Company’s cash and cash equivalents as of September 30, 2026 are insufficient to fund operations for at least the next 12 months from the date on which this Quarterly Report on Form 10-Q is filed with the SEC.
Since inception, we have regularly incurred losses and negative cash flows from operating activities. In 2025, we focused on further improving and increasing PHEXX and SOLOSEC access and delivered our fifth consecutive year of net sales growth. We have restructured some of our trade payables with extended terms and implemented measures to better align our cost structure with projected revenues. As discussed in Note 7 – Commitments and Contingencies, a significant portion of our trade payables are over 90 days old; a large portion of which relate to amounts due under a rebate program we are no longer participating in as well as amounts due related to various services we no longer receive.
| 41 |
| Table of Contents |
In 2026, we have continued to focus on top-line growth while maintaining a lean operating structure. We have also continued exploring opportunities for strategic options, organic growth, entry into new markets, and potential expansion of our product offerings beyond PHEXX and SOLOSEC.
As of September 30, 2026 the Company’s significant commitments include the Baker Notes, Adjuvant Notes, SSNs, and Aditxt Notes as described in Note 4 - Debt and the potential settlement amount with TherapeuticsMD as described in Note 7 - Commitments and Contingencies. The purpose of these commitments is to further the commercialization of PHEXX and SOLOSEC. Management’s plans to meet the Company’s cash flow needs in the next 12 months include generating revenue from the sale of PHEXX and SOLOSEC, further restructuring of the Company’s current payables, and obtaining additional funding through means such as the issuance of its capital stock, non-dilutive or dilutive financings, or through collaborations or partnerships with other companies, including license agreements for PHEXX and/or SOLOSEC in the U.S. or foreign markets, or other potential business combinations.
In addition, the Company faces significant near-term debt maturities, including approximately $34.6 million outstanding under the Adjuvant Notes and approximately $9.7 million outstanding under the Exchanged Senior Subordinated Notes as of September 30, 2026. On October 9, 2026, the Company entered into the Adjuvant Fifth Amendment, which extended the maturity date of the Adjuvant Notes to December 1, 2026, subject to earlier maturity upon certain specified events. The Exchanged Senior Subordinated Notes are also scheduled to mature on December 1, 2026. The Company’s existing liquidity is insufficient to satisfy these obligations at maturity, and the Company will need to obtain additional financing, negotiate further extensions or restructurings, or pursue other alternatives. There can be no assurance that the Company will be successful in doing so, and failure to satisfy or restructure these obligations could result in defaults, enforcement actions and other material adverse consequences to the Company’s financial condition and ability to continue as a going concern.
If the Company is not able to obtain the required funding through a significant increase in revenue, equity or debt financings, license agreements for our products in the U.S. or foreign markets, or other means, or is unable to obtain funding on terms favorable to the Company, there will be a material adverse effect on commercialization and development operations and the Company’s ability to execute its strategic development plan for future growth. If the Company cannot successfully raise additional funding and implement its strategic development plan, the Company may be forced to make further reductions in spending, including spending in connection with its commercialization activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in the interim condensed consolidated financial statements, suspend, or curtail planned operations, or cease operations entirely. Any of these could materially and adversely affect the Company’s liquidity, financial condition and business prospects, and the Company would not be able to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.
If we are unable to continue as a going concern due to our significant debt, much of which is due within the next six to twelve months, due to the default which Future Pak has alleged, or any number of other factors, we may have to liquidate our assets and, in doing so, we may receive less than the value at which those assets are carried on our consolidated financial statements. Any of these developments would materially and adversely affect the price of our stock and the value of an investment in our stock. As a result, our interim condensed consolidated financial statements include explanatory disclosures expressing substantial doubt about our ability to continue as a going concern.
The opinion of our independent registered public accounting firm on our audited consolidated financial statements as of and for the years ended December 31, 2025 and 2024 contained an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Future reports on our consolidated financial statements may include an explanatory paragraph with respect to our ability to continue as a going concern. Our unaudited condensed consolidated financial statements as of September 30, 2026 and December 31, 2025 and for the three and nine months ended September 30, 2026 and 2025 included in this Quarterly Report do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should we be unable to continue our operations.
Summary Statement of Cash Flows
The following table sets forth a summary of the net cash flow activity for each of the periods set forth below (in thousands):
| Nine Months Ended September 30, | 2026 vs. 2025 | |||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Net restricted cash and cash equivalents used in operating activities | $ | (625 | ) | $ | (2,023 | ) | $ | 1,398 | (69 | )% | ||||||
| Net restricted cash and cash equivalents used in investing activities | (2 | ) | (59 | ) | 57 | (97 | )% | |||||||||
| Net restricted cash and cash equivalents provided by financing activities | 366 | 2,181 | (1,815 | ) | (83 | )% | ||||||||||
| Net change in restricted cash and cash equivalents | $ | (261 | ) | $ | 99 | $ | (360 | ) | (364 | )% | ||||||
| 42 |
| Table of Contents |
Cash Flows from Operating Activities. During the nine months ended September 30, 2026, the net loss of $15.5 million was partially offset by $9.3 million net adjustments to reconcile net loss to net restricted cash and cash equivalents used in operating activities was the primary source of the cash used. Also contributing to the net restricted cash and cash equivalents used in operating activities were the decreases in accounts payable of $2.3 million, accrued expenses and other liabilities of $0.3 million, accrued compensation of $0.6 million, and contingent liabilities of $0.2 million as well as the increase in inventory of $0.1 million, partially offset by a decrease in trade accounts receivable of $8.8 million and prepaid and other assets of $0.3 million.
During the nine months ended September 30, 2025, the primary use of net restricted cash and cash equivalents in operating activities was driven by net loss of $2.4 million plus net adjustments to reconcile net loss to net restricted cash and cash equivalents used in operating activities of $4.4 million. The increase in cash used in operating activities was also driven by the payment of trade payables of $1.4 million, contingent liabilities of $0.5 million, and the purchase of inventory of $0.3 million. The use of restricted cash and cash equivalents in operating activities was partially offset by the collection of $5.4 million of accounts receivable and an increase in accrued expenses and other liabilities of $1.0 million and a decrease in prepaid expenses of $0.5 million.
Cash Flows from Investing Activities. During the nine months ended September 30, 2026, the primary use of net restricted cash and cash equivalents was the purchase of computer equipment. During the nine months ended September 30, 2025, the primary use of net restricted cash and cash equivalents was the payment of legal and accounting fees related to the acquisition of SOLOSEC which had previously been recorded as accounts payable.
Cash Flows from Financing Activities. During the nine months ended September 30, 2026, the primary source of net restricted cash and cash equivalents was the $0.7 million received related to the July 2026 HUB Note and the financing agreement with First Insurance Funding for total net proceeds to the Company of $0.4 million. These proceeds were partially offset by the payment of short-term debt and Notes – carried at fair value of $0.7 million. During the nine months ended September 30, 2025, the primary source of net restricted cash and cash equivalents was related to the Aditxt Notes and the financing agreement with First Insurance Funding for total net proceeds to the Company of approximately $2.8 million, partially offset by the payment of short-term debt and quarterly cash payments due under the Fourth Baker Amendment of $0.6 million.
Operating and Capital Expenditure Requirements
Our specific future operating and capital expense requirements are difficult to forecast. However, we can anticipate the general types of expenses and areas in which they might occur. In 2026, while we expect to maintain a lean operating structure at approximately the same level as 2025, should resources become available we may increase marketing spend to catalyze sales growth.
Contractual Obligations and Commitments
Operating Leases
Operating lease right-of-use assets and lease liabilities were $0.1 million each on September 30, 2026 and were $0.2 million each on December 31, 2025. See Note 7- Commitments and Contingencies for more detailed discussions on leases and financial statements information under ASC 842, Leases.
Other Contractual Commitments
As described in Note 7 - Commitments and Contingencies, in November 2019, the Company entered into a supply and manufacturing agreement with a third-party to manufacture PHEXX, with potential to manufacture other product candidates, in accordance with all applicable current good manufacturing practice regulations. There were no purchases under the supply and manufacturing agreement for the three months ended September 30, 2026 and $1.0 million in such purchases for the nine months ended September 30, 2026. There were $0.3 million and $1.1 million in purchases under the supply and manufacturing agreement for the three and nine months ended September 30, 2025, respectively.
Also as described in Note 7 - Commitments and Contingencies, on September 17, 2026, the Company entered into a manufacturing agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited, a Hong Kong company organized and existing under the laws of Hong Kong and Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited., a company organized under the laws of the People’s Republic of China (together, Zhaoke), pursuant to which Zhaoke agreed to manufacture and supply PHEXX in accordance with all applicable current good manufacturing practice regulations. Development and validation work is underway; there have been no purchases under this manufacturing agreement to date.
As described in Note 7 - Commitments and Contingencies, in prior periods, the Company had commitments related to the SOLOSEC asset acquisition including a commitment to purchase inventory from the seller through November 2026 at a pre-defined unit price; this commitment was terminated on March 13, 2026. The Company remains obligated to pay contingent liabilities and quarterly royalties based on SOLOSEC net revenue over the Earnout Term as described below and in Note 7 - Commitments and Contingencies.
| 43 |
| Table of Contents |
Intellectual Property Rights
As described in Note 7 - Commitments and Contingencies, the Company no longer owes royalties to Rush University pursuant due to the expiration of the Rush Patent.
As described in Note 7 - Commitments and Contingencies, as of July 14, 2024, the Company is obligated to pay a quarterly royalty in amounts equal to a certain percentage of the SOLOSEC U.S. net revenue. There are no minimum quarterly or annual royalty payment amounts. Such royalty costs were less than $0.1 million for the three and nine months ended September 30, 2026, respectively, and no milestones triggering payment of any contingent liabilities were attained. Such royalty costs were immaterial and $0.1 million for the three and nine months ended September 30, 2025, respectively. As of September 30, 2026, $0.1 million and $1.0 million related to the estimated fair value of the future payments related to the SOLOSEC acquisition, including sales-based payments, one-time payment, and quarterly royalty payments, was included in contingent liabilities – current and contingent liabilities – noncurrent, respectively, in the condensed consolidated balance sheet. Such amounts were $0.1 million and $4.6 million, respectively, as of December 31, 2025.
Other Matters
Recently Issued Accounting Pronouncements
For information with respect to recent accounting pronouncements, see Note 2 - Summary of Significant Accounting Policies to our interim condensed consolidated financial statements appearing in Part I, Item 1 of this Quarterly Report.
Critical Accounting Policies
No material changes to the critical accounting policies were disclosed in our Form 10-K for the year ended December 31, 2025.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Not applicable.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
As described in our Annual Report on Form 10-K for the year ended December 31, 2025, we identified material weaknesses in our internal control over financial reporting. As a result of these material weaknesses, our Chief Executive Officer (CEO) and Chief Financial Officer (CFO) have concluded that our disclosure controls and procedures are not effective to provide reasonable assurance that information required to be disclosed in the reports we file and submit under the Securities and Exchange Act is recorded, processed, summarized, and reported as and when required.
| 44 |
| Table of Contents |
Notwithstanding the conclusion by our CEO and CFO that our Disclosure Controls as of September 30, 2026 were not effective, and notwithstanding the material weaknesses in our internal control over financial reporting described more fully under Item 9A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, management believes that the interim condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q fairly present in all material respects our financial condition, results of operations and cash flows as of the date presented, and for the periods ended on such dates, in conformity with GAAP.
Remediation Activities:
During the current year, management continued implementation of its remediation plan, including strengthening review controls over financial reporting, enhancing documentation of accounting policies, and increasing oversight of the financial reporting process. Management continues to evaluate the material weaknesses discussed above and is implementing its remediation plan. However, assurance as to when the remediation efforts will be complete cannot be provided and the material weaknesses cannot be considered remedied until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. Management cannot assure readers that the measures that have been taken to date, and are continuing to be implemented, will be sufficient to remediate the material weaknesses identified or to avoid potential future material weaknesses.
Changes in Internal Control over Financial Reporting
Except for ongoing remediation activities described in the preceding paragraph, there were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations of Internal Controls
Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
| 45 |
| Table of Contents |
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Refer to Note 7 - Commitments and Contingencies to the unaudited condensed consolidated financial statements in this Form 10-Q for any required disclosure.
Item 1A. Risk Factors
There have not been any material changes to the risk factors disclosed in our Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 11, 2026.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
As of the filing date, the Company does not have any defaults on any Senior Securities which have not already been disclosed in a Current Report on Form 8-K.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
| (a) | None. |
| (b) | None. |
| (c) | Rule 10b5-1 Trading Plans |
During
the three months ended September 30, 2026, none of our directors or officers entered into,
| 46 |
| Table of Contents |
Item 6. Exhibits
The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index.
EXHIBIT INDEX
| Exhibit | Filed | Incorporated by Reference | ||||||||
| No. | Exhibit Title | Herewith | Form | File No. | Date Filed | |||||
| 10.1 | Fourth Amendment to Adjuvant Securities Purchase Agreement dated as of April 10, 2026 | 8-K | 001-36754 | 4/16/2026 | ||||||
| 10.2 | Exclusive Distributorship Agreement dated as of April 24, 2026 | 8-K | 001-36754 | 4/30/2026 | ||||||
| 10.3 | Promissory Note dated July 8, 2026 | 8-K | 001-36754 | 7/14/2026 | ||||||
| 10.4 | Manufacturing Agreement by and between the Company and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited and Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited dated September 17, 2026 | 8-K | 001-36754 | 9/23/2026 | ||||||
| 10.5 | Fifth Amendment to Adjuvant Securities Purchase Agreement dated as of October 9, 2026 | 8-K | 001-36754 | 10/15/2026 | ||||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||||||
| 32.1 | * | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||||||
| 101.INS | † | Inline XBRL Instance Document | X | |||||||
| 101.SCH | † | Inline XBRL Taxonomy Extension Schema Document | X | |||||||
| 101.CAL | † | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||||||
| 101.DEF | † | Inline XBRL Definition Linkbase Document | X | |||||||
| 101.LAB | † | Inline XBRL Taxonomy Extension Labels Linkbase Document | X | |||||||
| 101.PRE | † | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | ||||||||
| * | Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing. |
| † | The financial information of Evofem Biosciences, Inc. on Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed on November 13, 2026 formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Operations, (iv) the Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders’ Deficit, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements, is furnished electronically herewith. |
| 47 |
| Table of Contents |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EVOFEM BIOSCIENCES, INC. | ||
| Date: November 13, 2026 | By: | /s/ Ivy Zhang |
| Ivy Zhang | ||
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||
| 48 |